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Abstract
Evidence on cancer incidence in people with psychotic disorders, compared to the general
population, is equivocal, although those with psychotic disorders so have more advanced stage of
cancer at the time of diagnosis. The objective of this thesis was to compare cancer incidence and
stage at diagnosis for people with psychotic disorders, relative to the general population. Our
systematic review did not observe a significant difference in overall cancer incidence among
people diagnosed with psychotic disorders (RR = 1.08, 95% CI: 1.00 to 1.16), however people
with psychotic disorders were more likely to be present with advanced stage cancer at diagnosis
(OR = 1.22, 95% CI: 1.02 to 1.46). Our cohort study found an elevated incidence of cancer in
people with non-affective psychotic disorder, relative to the general population (IRR = 1.09,
95%CI: 1.05 to 1.12). Significant heterogeneity was found by cancer site. We found significant
effect modification by sex, which was removed when we excluded prostate cancer. Additionally,
we identified higher odds of more advanced stage at diagnosis in people with psychotic disorders
(OR = 1.23, 95% CI: 1.13, 1.34). These findings are indicative of a significant diagnostic delay
and a need to increase education and targeted access to care. Future research should examine the
confounding effects of lifestyle factors and anti-psychotic medication, as well as potentially
intermediary effects of cardiometabolic disorders.
Keywords: cancer, psychosis, schizophrenia, psychotic disorders, stage at diagnosis
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Summary for lay audience
It is unclear whether there is a higher incidence of cancer among people with psychotic disorders,
as many studies have been published which have found the incidence to be higher or lower than
the general population. There is evidence that people with psychotic disorders are more likely to
have more advanced stage cancer at diagnosis; however, this evidence is limited by shortcomings
and inconsistencies in the methodology of studies conducted on this topic. Although there have
been studies on stage at diagnosis and mortality from cancer in Canada, there have been no
Canadian studies to date which examine the incidence of cancer among people with psychotic
disorders. The provincial health administrative data under Canada’s universal healthcare system
provided an opportunity to answer these questions using large, population-based data. Our
objectives were to 1) examine the incidence of cancer in people with psychotic disorders and 2)
compare the stage of cancer at diagnosis in people with psychotic disorders to that of the general
population. Our systematic review did not find a difference in cancer incidence for people
diagnosed with psychotic disorders, however people with psychotic disorders were more likely to
have a more advanced stage cancer at the time they were diagnosed. Our cohort study found that
people with non-affective psychotic disorders had a higher incidence of cancer compared to the
general population. We also found that the incidence of certain cancers was higher and lower in
people with non-affective psychotic disorders. There was a difference in the incidence of cancer
among males with psychotic disorders relative to females with psychotic disorders. This difference
was removed when we exclude prostate cancer from our analyses, suggesting that prostate cancer
accounts for this difference that had been noted in previous studies. The differences found by
cancer site are likely the product of different levels of exposure to risk factors for developing
cancer among people with non-affective psychotic disorders, including smoking, cardiometabolic
iii

disorders, antipsychotic medication, and screening behaviour. Additionally, we found that people
with non-affective psychotic disorders were more likely to have a higher stage at the time they
were diagnosed with cancer. This indicates a delay in the diagnosis of cancer in people with nonaffective psychotic disorders. Furthermore, we found that people with non-affective psychotic
disorders were more likely to have missing data on stage at diagnosis. We recommend that future
studies examine the role of risk factors such as smoking, cardiometabolic disorders, and
antipsychotic medication in the risk of cancer among people with psychotic disorders. It is also
recommended that we implement programs which target cancer education, screening, and early
diagnosis among people with psychotic disorders, which may translate into more favorable health
outcomes.
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Chapter 1
1 Introduction
1.1 Thesis overview and description
1.1.1 Thesis overview
The risk of cancer among people with psychotic disorders remains a contentious issue.
Prior meta-analyses have produced equivocal results regarding whether the incidence of cancer is
elevated or decreased among people diagnosed with psychotic disorders, relative to the general
population.1,2 Furthermore, there is evidence to suggest that people with psychotic disorders are
more likely to be diagnosed with later stage cancer.3
Many theories have been proposed to explain differences in the incidence of cancer at
various sites throughout the body in people with psychotic disorders. These theories have
examined a number of biological, behavioural, and environmental factors influencing cancer risk. 1
For example, people with psychotic disorders are more likely to smoke, consume alcohol at higher
rates, and less likely to attend regular cancer screening. 4–6 Additionally, it is hypothesized that
people with psychotic disorders have a genetic factor which reduces the risk of developing
cancer.7–9
The overall aim of this thesis was to examine the incidence of cancer and stage at diagnosis
in people with psychotic disorders, compared to the general population. This chapter will present
background information on psychotic disorders and the physical health of people with psychotic
disorders, as well as information on factors affecting physical health among people with psychotic
disorders. Chapter 2 presents the findings from a systematic review and meta-analysis of prior

1

evidence on the incidence of both cancer overall, as well as site-specific cancers, and compared
the stage at diagnosis between people with any psychotic disorders and the general population.
Chapter 3 presents the findings from a population-based retrospective cohort study comparing the
incidence and stage at diagnosis of all cancers between people with non-affective psychotic
disorders (NAPD) and the general population in Ontario. Finally, chapter 4 includes an integrated
discussion of the findings of the two studies and future research directions.

1.2 Psychosis
1.2.1 Psychosis & psychotic disorders
Psychosis refers to a cluster of symptoms which includes delusions, hallucinations,
disorganized thought or speech patterns, and erratic or unusual behaviour.10 Those experiencing
an episode of psychosis have difficulty discerning between what is reality and what is not. The
cluster of disorders which feature psychotic symptoms are termed psychotic disorders, 11 although
psychosis may also occur as the result of drug use, metabolic disorders, strokes, or
neurodegenerative diseases, termed organic psychoses.11 The Diagnostic and Statistical Manual of
Mental Disorders Fifth Edition (DSM-V) characterizes schizophrenia spectrum disorder and other
psychotic disorders as including positive symptoms – delusions, hallucinations, and disorganized
thinking, speech and motor behaviour – as well as negative symptoms, which include flat affect
and withdrawal from social relationships.12
Delusions refer to beliefs held by someone which are fixed despite evidence to the contrary.
Delusions are seen as being either bizarre or ordinary. 12 Bizarre delusions are those which are
implausible, unable to be understood by members of that person’s culture, and not derived from
ordinary life experiences.12 Conversely, ordinary delusions are those which are derived from
2

everyday experiences and can be understood by other members of the person’s culture, but are not
accepted by other members of the persons culture. 12 Delusions are further categorized into
persecutory, referential, grandiose, erotomania, and nihilistic delusions, referring to their content
and theme.
Hallucinations are false perceptions occurring in the absence of external stimuli. 12
Hallucinations can occur in any sensory domain, whether it be visual, auditory, tactile, olfactory
and others.12 In the case of psychotic disorders, sensory hallucinations are the most common, often
presenting as voices which appear as distinct from the person’s own thoughts. 12
Disorganized thoughts, speech, and behaviour are often displayed as rapidly shifting topics,
difficulty concentrating, inability to follow a conversation, and difficulty performing everyday
tasks, such as maintaining personal hygiene.13
Broadly speaking, psychotic disorders are divided into affective and non-affective
psychotic disorders. Affective psychoses can be described as primarily mood disorders which also
include psychotic features, occurring primarily during episodes of mania and depression in people
with bipolar disorder and major depressive disorder.14 Non-affective psychotic disorders are those
which do not feature affective symptoms and include delusional disorder, schizophrenia spectrum
disorder, and unspecified non-organic psychosis.
Previous iterations of the DSM viewed schizophrenia as the most characteristic psychotic
disorder, with a series of sub-types. The inclusion of spectrum in ‘schizophrenia spectrum
disorder’ in the DSM-5 characterizes schizophrenia as a disorder existing along a spectrum with
other psychotic disorders.14 Abandonment of sub-categorization of schizophrenia is justified with
findings that sub-types were temporally unstable, in addition to being irrelevant to informing
treatment.15–17
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1.2.2 Physical health among people with psychotic disorders
People with psychotic disorders have higher mortality rates relative to the general
population.18–20 A meta-analysis of 34 studies found that those with psychotic disorders had a
standardized mortality rate of 3.09 (95% CI: 1.9 to 5.0) compared to those without, 21 translating
to a 15-year reduction in life expectancy.22 Approximately 60% of this excess mortality is
attributable to somatic comorbidities, which poses a complicating challenge in the treatment of
these disorders.23
People with psychotic disorders are at an increased risk of developing a number of
illnesses, including diabetes, gastrointestinal illnesses, cardiovascular illnesses, respiratory
illnesses, and HIV. A systematic review conducted by Rodrigues et al. found that those diagnosed
with psychotic disorders had a 69% increased risk of having two or more comorbidities and over
three times the risk of having three or more comorbidities, compared to those without psychotic
disorders.24
In particular, people with psychotic disorders are at a higher risk of cardiometabolic
disorders, with 66% of people with schizophrenia or bipolar disorder suffering from at least one
cardiometabolic disorder, and 39% suffering from at least two.25 These cardiometabolic
comorbidities often progress, resulting in cardiovascular disease and high risk of stroke. 26 People
with schizophrenia are at a 53% higher risk of cardiovascular disease, 71% higher risk of stroke,
20% higher risk of coronary heart disease, and 81% higher risk of congestive heart failure, relative
to the general population.26 Accordingly, these conditions account for a larger proportion of
mortality among people with psychotic disorders. An estimated two-thirds of people with
psychotic disorders die from coronary heart disease, compared to half in the general population.27
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Furthermore, antipsychotic have been shown to increase the risk of cardiometabolic disorders
among people with psychotic disorders.28,29

1.2.3 Risk factors among people with psychotic disorders
The higher risk of medical comorbidities, and cardiometabolic comorbidities in particular, are
a product of lifestyle, psychosocial, and environmental risk factors, in conjunction with long-term
use of antipsychotic medication.
Firstly, it has been consistently documented that people with PD are more likely to be of lower
socioeconomic status (SES).30–32 Low SES is associated with increased risk of a number of
conditions including cardiovascular disease, metabolic disorder, and obesity. 33–36 Furthermore,
low SES itself is an important prognostic factor and is associated with higher mortality risks for
cardiovascular disease and a number of cancers.37–41
Despite advancements in treatments, diagnostic practices, and a stability of deaths due to
suicide and accidents, the longevity gap for those with schizophrenia has been widening over the
past 50 years.42 It is hypothesized that increased rates of homelessness and poverty among people
with psychotic disorders is responsible for this trend.42 De-institutionalization in the 1970s was
defined by a shift in the management of psychiatric disorders from an inpatient institutional setting
to a community-based care approach.43 Although beneficial in some respects, the implementation
of de-institutionalization has shifted mental health supports to inadequate and defunded social
safety nets, resulting in higher rates of incarceration and homelessness.43
Secondly, people with psychotic disorders are more likely to be exposed to harmful
lifestyle factors. People with psychotic disorders are more likely to have a sedentary lifestyle and
poor eating habits.24,44–48 Men and women with schizophrenia are more likely to consume diets
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rich in saturated fats, total fats, and sodium, with higher overall caloric intake.49,50 In combination
with the low activity levels observed in people with schizophrenia, these factors contribute to
higher prevalence of obesity, hypertension, and insulin resistance. 51–53 Furthermore, the risk of
developing these conditions is worsened by antipsychotic medication54 – prior research suggests
that antipsychotic-naïve people with psychotic disorders already have a higher risk of diabetes and
obesity, however this risk is further increased once they begin treatment with antipsychotic
medication.28 A meta-analysis found that relative to drug-naïve patients, medicated, multi-episode
patients with schizophrenia had a significantly higher prevalence of hypertriglyceridemia, low
HDL cholesterol, and metabolic syndrome, a pre-cursor to diabetes.55 Antipsychotic medication
increases the risk of cardiometabolic disorders, obesity, and diabetes in particular, through a
number of pathways.56,57 Antipsychotics have been shown to overstimulate appetite through
antagonism of the dopaminergic, histaminergic, and serotonergic systems.58,59 Antipsychotics also
induce atherogenic dyslipidemia with increased fasting triglycerides and low serum HDL
cholesterol, increasing the risk of insulin resistance.56
Additionally, people with psychotic disorders are more likely to suffer from comorbid
alcohol and substance use disorders.60 It is estimated that 10.4% of people who have schizophrenia
spectrum disorder abuse alcohol, and 11.5% abuse other substances. 61 Alcohol has been causally
implicated in many major diseases, including various cancers, diabetes mellitus, epilepsy,
hypertensive heart disease, ischaemic heart disease (IHD), ischaemic and haemorrhagic stroke,
conduction disorders and other dysrhythmias, lower respiratory infections, and cirrhosis of the
liver.62 Additionally, alcohol abuse is associated with a number of adverse cardiovascular
outcomes, including: atrial fibrillation, myocardial infarction, and congestive heart failure.63
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People with schizophrenia and other psychoses have long been known to smoke at much
higher rates than the general population with demonstrated effects on health. 64,65 Smoking is
associated with a doubling of stroke risk, and a higher risk of coronary heart disease, peripheral
vascular disease, chronic lung disease, lung cancer, and bladder cancer. 66–68

1.3 Cancer
1.3.1 Cancer and cancer staging
Cancer, also referred to as malignant tumours or neoplasms, refers to a group of diseases
characterized by uncontrolled replication and proliferation of abnormal cells, caused by DNA
mutations, which may spread to other tissues and harm normal tissue. 69 Metastases refers to the
spread of cancerous cells through the circulatory or lymphatic system to distant tissues throughout
the body.69
Accurate staging of cancer allows physicians to describe the extent of disease in order to
inform appropriate treatment and allow comparison across cases worldwide.70 Cancer is most
commonly staged according to the TNM system developed by the American Joint Committee on
Cancer (AJCC) and International Union for Cancer Control (UICC). TNM is an abbreviation of
Tumour, Stage, and Metastases, representing each of the three criteria dictating the stage of a
particular cancer.70 The T category describes the tumour size and the extent to which it has spread
into nearby tissues, using T1 through T4, with increasing values indicating larger size and greater
spread.70,71 The N category is used to describe the number, size, or location of nearby lymph nodes
affected by the spread, using N1 through N3.70,71 The M category indicates whether the cancer has
metastasized to distant sites (M1), or not (M0).70,71
TNM staging can be condensed into the five-stage roman numeral staging.71 Stage 0
indicates carcinoma in situ, i.e. abnormal cells which have not yet spread to nearby tissue. 71 Stages
7

I – III indicate the presence of cancer, with increasing stage corresponding to tumour size and
regional spread.71 Stage IV indicates metastases of the cancer to distant sites.71 Tumour grading
refers to the pathological determination of differentiation of tumour cells. 72 Well-differentiated
tumour cells have structure and resemblance similar to normal tissue and progress more slowly,
whereas undifferentiated or poorly-differentiated cells lack typical tissue structure and progress
more aggressively.72
Cancer may be staged at different points throughout the diagnosis to treatment
continuum.73 Most commonly, clinical staging involves the staging of cancer prior to treatment,
during a physical exam, imaging, or biopsy.73 Pathological staging may be performed on the
tumour excised during a surgical procedure.73 Post-neoadjuvant therapy staging is performed prior
to non-surgical treatments to assess the effectiveness of said treatment on reducing tumour size.73
Retreatment staging is performed in the event that a cancer recurs or progresses.73

1.3.2 Cancer screening
Over recent decades, substantial efforts have been made in high income countries to
implement screening programs for early identification of cancer and pre-cancerous lesions.
Overall, these efforts have resulted in significant reductions in patient mortality, as well as
improved treatment and management of cancers. However, increased screening has not provided
consistent benefit for all cancer types.
As part of the Colon Cancer Check program in Ontario, participation in fecal occult blood
tests increased from 7.6% to 14.8% and large bowel endoscopy increased from 3.4% to 5.7%.74
Increased rates of colonoscopy and colorectal cancer screening were associated with reductions in
colorectal cancer mortality.75 A useful feature of colonoscopies is the ability to remove precancerous adenomatous polyps during the procedure, aiding substantially in reducing colorectal
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cancer mortality.76 Dramatic increases in screening from 2000 to 2008 resulted in increases in the
incidence of colorectal cancer cases, largely from increased detection of early-stage cancers.77
More targeted efforts in cancer screening reduced colorectal cancer incidence to rates below those
from the period prior to 2000.77
Introduction of the pap smear has allowed for screening of pre-cancerous lesions and earlystage cervical cancer.78 Widespread pap smear use has resulted in a significant decrease in earlyand late-stage cervical cancer incidence among women in Canada.79 These changes also coincide
with vaccination for HPV; however, it is estimated that somewhere between 105,000 and 492,000
cases of cervical cancer have been prevented as a result of screening. 80,81 More recently, HPV
DNA testing has allowed for greater and more advanced detection of cervical cancer.82
From the early 1980’s to the early 1990’s, there was a dramatic increase in prostate cancer
screening, mainly through prostate-specific antigen (PSA) testing, resulting in a 6.4% increase in
incidence every year, mainly from detection of early stage prostate cancer. 83 However, this
increase in screening did not result in reductions in prostate cancer mortality.83 In Canada, the
introduction of prostate specific antigen (PSA) testing resulted in dramatic increases in prostate
cancer incidence from 1990 to 1993.84 It has been found that the use of PSA, a highly sensitive
test, is responsible for significant overdiagnosis of prostate cancer cases which would have never
been diagnosed in the absence of the screening program, and consequently unnecessary
treatment.84,85 Similarly, these trends were accompanied by increases in radical prostatectomies.83
A similar situation has been found for breast cancer. Revised examinations of the results
of the Canadian National Breast Cancer Screening Study found that 55% of breast cancer among
women aged 40 to 49 and 16% for women aged 50 to 59.86

9

1.3.3 Cancer etiology
The development of cancer is the result of an accumulation in mutations of genes which
serve to regulate cell growth and proliferation and maintain the integrity of genetic material. 87
These mutations can be inherited, happen at random, or be acquired somatically through exposure
to carcinogens.88 A number of specific genes associated with the development of many cancers,
such as the BRCA genes, have been identified.89 As an example, it is estimated that the presence
of mutations at the BRCA 1/2 genes increases the lifetime risk of breast cancer in women from
12% to somewhere between 40% and 85%.90
The remainder of oncogenesis is caused by physical, chemical, and biologic carcinogens. 88
Physical carcinogens are defined as agents which produce cancer through physical properties and
physical effects, which include radiation, temperature, mechanical trauma, and solid materials. 91
Asbestos exposure is an identified physical carcinogen which resulted in inflammation, fibrosis,
and irritation of the lung tissue, ultimately causing lung cancer. 92 Because asbestos was a
commonly used building material, its widespread exposure accounts for 5 to 7% of all lung cancer
worldwide and 1% of mortality in developed countries.93 Another example is the role of ultraviolet
(UV) radiation in producing melanoma.94
Chemical carcinogens differ in that they produce cancer as a result of chemical properties
and effects.95 Most chemical carcinogens are metabolized into mutagenic electrophiles, which are
in turn attracted to nucleophilic species such as DNA and protein, thereby causing damage. 95
Smoking is an identified chemical carcinogen responsible for lung, bladder, and head/neck
cancers.66,67,96,97
A biological carcinogen is any biological substance involved in cancer development,
including plants, animals, bacteria, fungi, or viruses.98 Biological carcinogens can act directly to
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induce carcinogenesis by incorporation of genome, or inducing expression of oncogenes. 98 The
human papilloma virus (HPV) is a sexually transmitted infection which disrupts cytokine
expression and interferes with the interferon pathway through incorporation of its genome into the
host’s cells, resulting in uninhibited cell growth and proliferation.99 Biological carcinogens may
also act indirectly by altering metabolizing enzymes, producing inflammation or other
carcinogenic toxins.98 Infection with H. pylori, hepatitis B virus (HBV), and hepatitis C virus
stimulate the production of pro-inflammatory cytokines, thereby producing chronic inflammation
and DNA damage through reactive oxygen species (ROS).100

1.3.4 Cancer risk factors
Exposure to carcinogenic compounds is determined by a combination of environmental
exposures and lifestyle factors. Because there are innumerable lifestyle and environmental
exposures that are associated with carcinogenesis, this background will not provide an exhaustive
overview of these factors. Rather, we will provide some detail on a number of factors relevant to
this thesis. As previously mentioned, tobacco smoke represents a significant chemical carcinogen,
exposure to which may be considered either a lifestyle factor by smoking directly, or indirectly
through environmental exposure.
It is estimated that diet represents 30-35% of the risk contribution to cancer.101
Carbohydrate intake, higher glycemic index diet, insulinemia, and type II diabetes are associated
with a higher risk of breast cancer.102–105 Additionally, diets high in processed and red meat are
associated with increased risk of colorectal, bladder, kidney, esophageal, and endometrial
cancer.105–108 A meta-analysis of prospective cohort studies found that for every 100g/day increase
in red meat consumption, there was an associated 17% increased risk (95% CI: 1.05 to 1.31) of
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colorectal cancer.108 Dietary fibre intake has demonstrated an inverse-dose response relationship
with breast and colorectal cancer risk.109,110
Alcohol is another chemical carcinogen associated with the development of a wide variety
of cancers. An Australian cohort study of participants over 45 years old, found that increasing
alcohol consumptions was associated with a significant increase in the risk of upper aerodigestive,
oral, pharyngeal, esophageal, colorectal, liver, and breast cancer.111
Carcinogenesis occurring through environmental or occupational exposure typically occurs
via indoor and outdoor air pollutants, as well as pollutants in soil and water. 112 These exposures
vary significantly by socioeconomic status (SES), ethnicity, and other sociodemographic
characteristics, such that cancer incidence does as well. Ecological studies of air pollution have
found that lung cancer risk is elevated among those living in urban areas with exposure to higher
levels of pollution, relative to people living in rural areas.112 The European Study of Cohorts for
Air Pollution Effects (ESCAPE), examining pollution levels in 17 European countries, found that
particulate matter air pollution is significantly associated with lung cancer incidence. 113 Regarding
SES, lower income, and racialized communities are more likely to reside near industrial facilities,
exposing them to toxic and carcinogenic byproducts.114–116 These trends are consistently
demonstrated globally, with the exception of some European countries.116 Additionally, children
of parents living in more deprived areas with less education have a higher risk of environmental
exposure to tobacco smoke.117 The co-occurrence of ambient air pollution and tobacco smoke have
an additive synergistic effect on lung cancer risk.118 As such, those with lower SES and less
education have a higher odds of developing lung cancer, cervical cancer, head and neck cancers,
and cancers of the gastrointestinal tract.119,120 This association between lower SES and higher
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incidence of cancers persists in Canada which has a universal healthcare system, suggesting that
these differences are much more deeply rooted than barriers as a result of cost. 120

1.4 Cancer among people with psychotic disorders
Compared to other physical health issues, our understanding of the risk of cancer among people
with psychotic disorders is much more unclear. In 1909, the Report of the Commissioners in
Lunacy hypothesized that people with psychotic disorders experienced lower rates of cancer,
relative to the general population.121 Since that time, a large number of cohort studies have been
conducted, producing conflicting results.7,8,122–124 A number of meta-analyses examining cancer
incidence in people with schizophrenia have examined varying subsets of the literature,
differentiated by methodology and cancer sites.1,2,125–127 These meta-analyses have produced
similarly conflicting findings. There is also evidence to suggest that people with psychotic
disorders are more likely to present with more advanced stage cancer at diagnosis, indicative of a
diagnostic delay.6 Prior meta-analyses have only synthesized estimates of site-specific cancer
incidence for a handful of sites, failing to explore the full scope of site-specific incidence in people
with psychotic disorders, relative to the general population.

1.5 Rationale and objectives
There still remains significant debate regarding whether people with psychotic disorders
experience an elevated incidence of cancer compared to the general population. Furthermore, the
current literature on stage-at-diagnosis of cancer among people with psychotic disorders is limited
by a variety of methodological shortcomings and inconsistencies. This thesis will examine the
incidence of cancer and stage and stage at diagnosis in people with psychotic disorders, relative to
the general population, with two overarching objectives:
13

1. To review the literature regarding cancer incidence and stage at diagnosis among people
with psychotic disorders (Chapter 2).
2. To examine cancer incidence and stage at diagnosis in people with psychotic disorders in
Ontario using a retrospective cohort design based on health administrative data (Chapter
3).
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Chapter 2
2 Cancer Incidence and Stage at Diagnosis among People with
Psychotic Disorders: Systematic Review and Meta-Analysis.
2.1 Abstract
Background: A number of studies suggest a lower incidence of cancer in those with psychotic disorders
compared to the general population, whereas others have found the opposite. Additionally, other research
has found that people with psychotic disorders have more advanced stage cancer at diagnosis and higher
cancer-specific mortality rates, suggesting disparities in access to treatment. This systematic review
examined the incidence and stage at diagnosis of cancer among people with psychotic disorders, relative
to the general population.
Methods: We performed an electronic search of the MEDLINE, PsycINFO, EMBASE, and CINAHL
databases. Articles were included if they examined cancer incidence in people with psychotic disorders
and used a non-psychotic or general population comparison group. Random-effects meta-analyses were
used to examine cancer risk and stage at diagnosis in people with psychosis, relative to the general
population.
Results: Thirty-nine articles were included in the review. The pooled age-adjusted risk ratio for all cancers
in people with psychotic disorders was 1.08 (95% CI: 1.00 to 1.16), relative to the general population.
People with psychotic disorders had 22% higher (95% CI: 2% to 46%) odds of metastases at diagnosis,
compared to people without psychotic disorders.
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Conclusions: Our systematic review did not observe a significant difference in overall cancer incidence
among people diagnosed with psychotic disorders, however people with psychotic disorders were more
likely to be present with advanced stage cancer at diagnosis. This may reflect a need for improved
education and access to cancer screening and diagnosis for patients diagnosed with psychotic disorders.
Future studies are encouraged to account for a wider range of confounding factors when examining cancer
incidence in people with psychotic disorders.
Keywords: cancer, psychosis, schizophrenia, psychotic disorders, stage at diagnosis

2.2 Background
People who suffer from psychotic disorders, including schizophrenia spectrum disorder, have
elevated rates of mortality compared to the general population,18,19 and it is estimated that 59% of this
excess mortality is attributable to concurrent medical illnesses.128 The cause of these disparities is thought
to be the product of biological mechanisms and a number of lifestyle factors – such as poor diet, smoking,
drug use, and lack of exercise – as well as due to ongoing use of medications, healthcare seeking
behaviour, and differential treatment within the healthcare system.18,24 Extensive research has been done
examining concurrent medical illnesses in those with psychotic disorders, definitively identifying elevated
incidence of liver disease, renal disease, diabetes, congestive heart failure, and myocardial infarction. 19
However, the incidence of cancer in people with psychotic disorders, relative to the general
population, has remained an area of contention since the Report of the Commissioners of Lunacy in
1909,121,129,130 which first reported lower rates of cancer in patients with schizophrenia. Subsequent studies
examining the incidence of cancer in those with psychotic disorders have produced contrasting results.
Some have suggested a lower incidence of cancer, relative to the general population,8,122,123 whereas others
have found the opposite.7,124 Six prior meta-analyses have examined cancer incidence across various sites
in people with schizophrenia.1,2,125–127,131 A meta-analysis of multiple cancer sites, performed by Catts et
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al., found no difference between the overall cancer incidence in people with schizophrenia and the general
population; however, an elevated incidence of lung and breast cancer was found.1 The elevated incidence
of lung cancer was reduced after controlling for smoking prevalence. These results conflict with a similar
meta-analysis, which found an slightly decreased risk of cancer overall among people with schizophrenia,
as well as decreased risk of colorectal cancer, prostate cancer, and lung cancer among women with
schizophrenia.2 Other meta-analyses examining cancer incidence at specific sites have identified an
increased risk of breast cancer,1,126,131 a decreased incidence of liver cancer,125 and no difference in lung
cancer incidence for people with schizophrenia, relative to the general population.127
There is also evidence that people with psychotic disorders may be more likely to present with a
more advanced stage of cancer at diagnoses. presence of distant metastases. A meta-analysis of stage at
diagnosis and cancer-specific mortality found that those with pre-existing mental illnesses, including
psychotic disorders, had a 19% higher odds (OR: 1.19, 95%CI: 1.06, 1.33) of advanced stage cancer at
diagnosis, whereas people with psychotic disorders had 30% higher odds (OR: 1.30, 95%CI: 1.01, 1.68),
relative to those without pre-existing mental illnesses.6 This meta-analysis examined all mental illnesses,
with psychotic disorders representing one category of disorders.
All of the previous meta-analyses of cancer incidence have exclusively focused on people with
schizophrenia, and restricting inclusion criteria to specific measures of incidence, significantly reducing
the scope to a subset of the available literature, regarding cancer incidence among people with psychotic
disorders, largely excluding affective psychoses, such as bipolar disorder. Furthermore, prior metaanalyses have only synthesized estimates of site-specific cancer incidence for a handful of sites, failing to
explore the full scope of site-specific incidence in people with psychotic disorders, relative to the general
population.
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The objective of this study was to perform a systematic review and meta-analysis of literature
comparing the incidence of any type of cancer and stage at diagnosis among people with psychotic
disorders, relative to the general population.

2.3 Methods
This systematic review was pre-registered with PROSPERO (Protocol # CRD42020179833). We
followed the PRISMA reporting guidelines for systematic reviews and meta analyses, and the checklist
can be found in Appendix X.132

2.3.1 Search Strategy and Study Selection
We conducted electronic literature searches of the MEDLINE (1966-2020), PsycINFO (1880 2020), and EMBASE (1947-2020) databases via Ovid, as well as the CINAHL (1937-2020) database via
EBSCOhost, in May 2020. A research librarian at the University of Western Ontario was consulted
regarding the search terms and selection of databases. The search terms were developed following
examination of subject headings and related terms pertaining to cancer incidence, stage of cancer, and
psychotic disorders in each database. The final search strategy for each database and their respective
number of results can be found Appendix A2. No restrictions were placed on date of publication.
Additional articles were identified via forwards and backwards citation tracing.
The articles underwent title and abstract screening by a single reviewer (JW). At this stage, articles
were excluded if they were not related to physical illness among people with mental illnesses, or if there
was explicit mention of study design other than case-control, cohort, or cross-sectional design. Full-text
screening was done in duplicate by two reviewers (JW, JCW). Conflicts between reviewers were resolved
by consensus. If consensus could not be reached, a third reviewer (KKA) was introduced as a tiebreaker.
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Studies were included if they examined cancer incidence or stage at diagnosis in a sample of people
with a diagnosis of any psychotic disorder (schizophrenia, schizoaffective disorder, delusional disorder,
affective psychoses, psychosis NOS) using standardized diagnostic criteria, such as DSM or ICD, as well
as a non-psychotic or general population comparison group. Furthermore, studies which used a cohort,
case-control, or cross-sectional study design were included; those which used other study designs,
including randomized control trials and descriptive studies, were excluded. Studies that included both
clinical diagnoses and standardized interviews were eligible for inclusion. No restrictions were placed on
the age of the sample. Studies which included people with other non-psychotic mental disorders, without
providing stratum specific estimates for psychotic disorders, were excluded. Non-peer reviewed studies
were excluded. No restrictions were placed on the date of publication.

2.3.2 Data Extraction
Data were extracted independently, in duplicate, by two reviewers (JW, JCW) using a pilot tested
data extraction tool. Descriptive data pertaining to the following items were collected: year of publication,
country, study objectives, study design, participant source, inclusion/exclusion criteria, psychiatric
diagnoses of participants, age of participants, sample size, and sex breakdown. We extracted crude and
adjusted estimates of the cumulative incidence of overall and site-specific cancers, as well as estimates
stratified by psychiatric diagnosis. In addition, the number of people with each stage at diagnosis were
extracted, where available, for people with psychotic disorders and those without.
The risk of bias for each study was assessed independently by two reviewers, using the Tool to
Assess Risk of Bias in Cohort and Case-Control Studies by CLARITY.133
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2.3.3 Data Synthesis
Data collected from included articles were summarized both qualitatively and quantitatively. Study
characteristics and a summary of findings were displayed in tables. Articles which contained suitable data
for quantitative synthesis were included in a random effects meta-analysis, using the Dersimonian-Laird
estimator of residual heterogeneity, to produce pooled estimates of the incidence of cancer relative to the
general population, as well as odds ratios for stage at diagnosis.134 If studies did not report an age-adjusted
effect measure of incidence and associated confidence intervals, or count data for stage at diagnoses, they
were excluded from the quantitative synthesis.
Two meta-analyses of cancer incidence were performed on the age-adjusted effect measures, all
of which were assumed to approximate an age-adjusted risk ratio.131 To explore whether the use of varying
effect measures influenced the pooled effect estimate, sensitivity analyses were performed using subgroup
analyses with consistent measures. Sensitivity analyses of outlier influence on pooled estimates were
conducted by identifying outliers using the ‘find.outliers’ function in the dmetar package in RStudio, and
excluding those studies from the meta-analysis. The first meta-analysis examined the relative risk of
cancer at all sites in people with psychotic disorders, relative to the general population. Estimates of the
incidence of site-specific cancers were excluded from this analysis. The second meta-analysis examined
the incidence of site-specific cancers among people with psychotic disorders, relative to the general
population.
Regarding the meta-analysis of stage at diagnosis, two-by-two tables were constructed of the
number of people with stage IV or metastases at diagnosis among those with psychotic disorders and those
without. These tables were used to produce odds ratios of metastases at diagnosis among those with
psychotic disorders relative to those without.
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Results of these meta-analyses were displayed in a forest plot stratified by psychotic disorder
diagnosis, as previous studies have identified differences in incidence by psychiatric diagnosis.135,136 Subgroup differences by psychotic disorder diagnosis were examined using a Q-test. Heterogeneity in each
meta-analysis was assessed using an I2 statistic. An I2 statistic of 25%, 50%, or 75% indicates low,
moderate, and high levels of heterogeneity, respectively.137 Publication bias was assessed by visual
assessment of funnel plots, in addition to an Egger’s test of asymmetry.138
All meta-analyses were conducted in Rstudio v1.2.5033,139 using the metafor package,134 and
findings are presented as risk ratios (RR) and odds ratios (OR) with corresponding 95% confidence
intervals (CI).

2.4 Results
2.4.1 Search results
An outline of exclusions at each step of the screening process can be found in Figure 1. The electronic
literature search initially returned 848 unique citations, and an additional five articles were identified from
forwards and backwards reference searching. Of these, 729 were deemed ineligible upon review of title
and abstract.
We screened the full-text of 120 articles, and 81 were excluded for the following reasons: did not
report data on incidence or stage at diagnosis (n=44); not a case-control, cross-sectional study, or cohort
study (n=14); sample did not include people with psychotic disorders, or did not differentiate people with
psychotic disorders from other mental illnesses (n=16); did not have a comparison group or the
comparison group included people with other mental illnesses (n=2); or no full-text version was published
or available (n=3). Forty articles were deemed eligible for inclusion in the review.
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There were a number of studies which met a majority of the inclusion criteria, but were excluded due
to the absense of a single criterion. A Danish cohort study examining colon cancer in patients with serious
mental illnesses was excluded because the authors did not distinguish between those with psychotic
disorders and those with other psychiatric illnesses.140 Similarly, a study examining antipsychotic use on
gastric cancer risk was excluded on the basis that the provided odds ratios of developing cancer were not,
in fact, measures of cancer incidence as stated in the inclusion criteria. 141

2.4.2 Study Characteristics
The characteristics of included studies can be found in Table 2.1, and a comprehensive summary of
findings table can be found in Appendix B1. Thirty studies examined incidence of cancer, eight examined
stage at diagnosis, and one study included information on both incidence and stage at diagnosis. Thirtyeight of the included studies were retrospective cohort studies of health administrative data, and one was
a case-control study using a clinical sample. As such, the majority of studies ascertained the outcome of
cancer via linkage to a cancer registry, with a median follow-up period of 15.5 years (IQR: 10.0 to 26.3).
Thirty-five studies included people with schizophrenia in their sample, twelve included people with
schizoaffective disorders, thirteen included people with affective psychoses, and four included people with
psychosis NOS. Two studies did not specify which psychotic disorders were included.
In terms of the comparison group, twenty-four studies used a general population comparison group,
whereas fifteen studies used a sample of people without psychotic disorders selected from a list of patients
or people eligible for a benefits program, three of which were matched on age, sex, and other covariates.
All studies that reported measures of incidence adjusted for confounding factors in their estimates of
incidence, with six additionally reporting crude measures. The confounding factors that were adjusted for
in each estimate can be found in the extended summary of findings table in Appendix A3.

22

2.4.3 Risk of Bias
The complete findings of the risk of bias assessment can be found in appendix A3, and a summary
of those findings is displayed in Figure 2.2. The most common issues identified across included studies
were the inability to ensure that the outcome of interest was not present at the beginning of each study,
assessment of exposure, inclusion of important confounding factors, and missing data. Seventy-four per
cent of studies presented an intermediate risk of bias for assessment of exposure, with a significant portion
of remaining studies missing information on this item (12.8%). Regarding the inclusion of important
confounding factors, 66.7% of studies presented intermediate risk of bias and 28% presented a high risk
of bias. Only 51% of studies had a low risk of bias for ensuring that cancer was absent at the start of the
study. A large portion of studies (49%) did not report the extent of missing data. As most studies used
health administrative data, the assessment of outcome and measurement of confounding factors were
found to have a low risk of bias in the majority of studies.

2.4.4 Meta-Analyses
A total of eight studies were excluded from the quantitative synthesis for the following reasons:
articles did not report data for a meta-analysis (n = 5) or reported sources of data that were duplicate of
another study included in the review (n = 3). Thirty-one studies remained with suitable data for metaanalysis, with twenty-four studies reporting incidence estimates, six reporting stage at diagnosis, and one
reporting both. Sixteen studies reported standardized incidence ratios (SIR), five reported incidence rate
ratios (IRR), three reported hazards ratios (HR), and three reported standardized risk ratios (RR). For
studies included in the meta-analysis that reported data on stage at diagnosis (n = 7), five included those
diagnosed at stages I through IV, while the remainder only reported the proportion of patients with local
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vs. metastasized cancers. Two studies produced adjusted odds ratios using logistic regression: one
adjusting for age, gender, comorbidities, income, and type of cancer, while the other adjusted for age and
gender.

2.4.4.1 Overall Cancer Incidence
The results of the meta-analysis of cancer risk are displayed in Figure 2.5. The overall pooled estimate
of age-adjusted risk ratio of cancer in people diagnosed with psychotic disorders, relative to the general
population, was 1.08 (95% CI: 1.00, 1.16). This suggests that the age-adjusted incidence of cancer among
people with psychotic disorders was slightly elevated, relative to the general population, although the 95%
CI includes the possibility of a null effect. A very high level of heterogeneity was found across ageadjusted measures of cancer risk (I2 = 95.7%, tau2 = 0.05). Seven estimates were considered outliers, and
removal of these produced a pooled estimate of 1.05 (95% CI: 1.02 to 1.10), as well as substantially
reduced statistical heterogeneity (I2 = 70.1%; tau2 = 0.006).
Evaluation of the funnel plot displayed in Appendix 2F did not suggest publication bias, and Egger’s
test of asymmetry indicated that there was insufficient evidence to suggest asymmetry in the funnel plot
(z = 0.4169, p = 0.6768)
Based on the available information provided by the studies, sub-group analyses were conducted
according to affective psychotic disorders, non-affective psychotic disorders, and samples which included
a mix of affective and non-affective psychotic disorders. A Q-test revealed no statistically significant
difference in cancer incidence between psychotic disorders (Q M = 9.23, df = 4, p = 0.06).
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2.4.4.2 Site-Specific Cancer Incidence
We were able to produce site-specific estimates of cancer risk for twenty-six cancer types (Figure
2.6). Elevated risk ratios were found for cancer of the brain (RR: 1.41, 95%CI: 1.07, 1.75), breast (RR:
1.22, 95%CI: 1.02, 1.43), nasopharynx (RR: 1.18, 95%CI: 1.02, 1.34), cervix uteri (RR:1.33, 95%CI:
1.15, 1.51), and corpus uteri (RR:1.71, 95%CI: 1.17, 2.25). Lower risk ratios were found for cancers of
the colon and rectum (RR: 0.87, 95%CI: 0.80, 0.95), prostate (RR:0.54, 95%CI: 0.47, 0.62), and skin (RR:
0.72, 95%CI: 0.63, 0.81).

2.4.4.3 Stage at Diagnosis
The results of the meta-analysis of stage at diagnosis are displayed in Figure 2.7. The pooled
estimate of the odds ratio of metastases at diagnosis for people with psychotic disorders, relative to the
general population, was 1.22 (95% CI: 1.02 to 1.46). A very high level of heterogeneity was found (I 2 =
96%, tau2 = 0.05). Three estimates were considered outliers, and removal of these produced a pooled OR
of 1.12 (95% CI: 1.00 to 1.25), as well as reduced statistical heterogeneity (I2 = 85.20%; tau2 = 0.009).
However, these pooled analyses include a small number of heterogenous studies.
Evaluation of the funnel plot displayed in Appendix 2G did not reveal any evidence of publication
bias. Egger’s test of asymmetry indicated that there was insufficient evidence to suggest asymmetry in the
funnel plot (z = 1.4635, p = 0.1433). However, the power of the egger’s test to detect publication bias may
have been limited by the number of studies.138

2.5 Discussion
This meta-analysis did not find a significant difference in overall cancer risk for those with
psychotic disorders, relative to the general population. Prior meta-analyses of overall cancer incidence in
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people with psychotic disorders have focused on people with schizophrenia. One such meta-analysis found
an decreased risk of cancer (SIR = 0.90, 95% CI: 0.81 to 0.99),2 whereas another found no difference (SIR
= 1.05, CI 0.95 to 1.15).1 The current systematic review and meta-analysis builds on this prior evidence
by examining cancer incidence as well as stage at diagnosis in people with other psychotic disorders, in
addition to schizophrenia, by including a broader range of estimates of incidence as well as data on stage
at diagnosis.
It was first hypothesized that people with psychotic disorders had a lower incidence of cancer, relative
to those without psychotic disorder,121 and since that time a wide range of theories to explain this
phenomenon have been proposed. Three studies compared cancer incidence among people with
schizophrenia to both relatives without schizophrenia and to the general population. 7–9 Relatives of people
with schizophrenia were found to have a lower incidence of cancer, relative to the general population. The
authors of these studies hypothesized that there may be shared genetic factors that are associated with
schizophrenia and a lower risk for developing cancer.
Other studies have examined dopamine, and its role in the regulation of cell proliferation, as an
important factor affecting cancer risk in people with psychotic disorders. 142,143 Indeed, the effects of
dopamine antagonists, including antipsychotics and anti-emetics, have been explored through a number
of models, with effects on cancer risk largely heterogeneous by cancer site. Both in vitro and rodent
models have demonstrated largely anti-cancer effects via a number of pathways, with the exception of
breast and liver cancer in females, where dopamine antagonists were found to increase risk. 144 However,
the evidence for a causal relationship between antipsychotic exposure and cancer is not proven. 145
The effect of dopamine antagonists on breast cancer has been examined in epidemiological studies,
wherein exposure to dopamine antagonists is significantly associated with an increased risk of breast and
endometrial cancer.146–148 Although the mechanism of action is unclear, it is also thought that
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antipsychotic medication may increase levels of prolactin, which is associated with breast
carcinogenesis.145,149 A number of included studies identified an elevated risk of sex-specific cancers
among females with schizophrenia, namely cancer of the breast, uterus, and cervix.8,136,150–154 One such
study found the risk of all cancers to be higher among females with schizophrenia, relative to the general
population, but not among males with schizophrenia.155 This difference was eliminated when femalespecific cancers were excluded from the analysis.155 Our meta-analysis found the risk of breast, cervical,
and uterine cancer to be significantly elevated among females with psychotic disorders, which is consistent
with the findings of prior meta-analyses of breast cancer in people with schizophrenia.1,126,131 To our
knowledge, there are no prior meta-analyses of the risk of cervical and uterine cancer among women with
psychotic disorders.
Antipsychotic medication has also been associated with a reduced risk of prostate and colorectal
cancer.156 A cohort study published in 1992 identified a significantly lower incidence of prostate cancer
among males with schizophrenia who were prescribed large doses of phenothiazines.157 It is hypothesized
that elevated prolactin levels suppress testosterone levels, an important factor in prostatic tumour
growth.158 Regarding colorectal cancer, antipsychotic medication has been found to exert anti-oncogenic
effects in vitro via downregulation of fibroblast growth factor receptors in colorectal cancer cells.159 In
the current review, people with psychotic disorders were found to have a significantly reduced risk of both
prostate and colorectal cancers.
Other health and behavioral factors, such as cardiometabolic disorders and smoking, might have a
bigger influence on cancer risk.145 People with psychotic disorders have a higher risk of developing
cardiometabolic disorders such as cardiovascular disease, diabetes, and obesity. This is largely a result of
sedentary lifestyle and poor eating habits, the effects of which are exacerbated by exposure to antipsychotic medication.24,44–48
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Diabetes and obesity are established risk factors for a variety of cancers, including breast and
colorectal cancer.104,105 However, diabetes is negatively associated with prostate cancer risk and PSA score
as a result of reduced insulin response and lower levels of testosterone.160–162
Additionally, people with schizophrenia have been found to smoke at much higher rates compared
to the general population.163 Although the association between smoking and both lung and bladder cancer
is well established and thoroughly documented,66,67 this meta-analysis did not find a significantly elevated
risk of lung or bladder cancer among people with psychotic disorders, which is similar to previous metaanalyses.1,2,127 However, one prior meta-analysis found an elevated risk of lung cancer among people with
schizophrenia, which was attenuated when estimates were adjusted for smoking behaviour. 1
Screening uptake represents another factor which may influence both observed cancer incidence
as well as stage at diagnosis among people with psychotic disorders. Women with psychotic disorders
have significantly lower odds of receiving cervical and breast cancer screening, compared to women
without psychotic disorders.164–167 However, prior meta-analyses have challenged the hypothesis that the
lower incidence of particular cancers in people with psychotic disorders are the result of delayed detection,
citing post-mortem data which found that undiagnosed cancer was a rare event. 1 This review further
suggested that the aggressive nature of lung and bladder cancer, along with the rapid course of these
cancers, makes it very unlikely that there would be diagnostic delay for people with psychotic disorders. 1
While it is accurate that cancer is unlikely to go entirely undetected, this does not preclude the existence
of a diagnostic delay. Furthermore, the more advanced stage at diagnosis in this population is in and of
itself indicative of this delay. Furthermore, this diagnostic delay has been shown to account for a portion
of the difference in cancer mortality between people with psychotic disorders and those without. 168 Our
review identified a significantly elevated odds of metastases at diagnosis for people with psychotic
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disorders. Although we do not have data on stage at diagnosis for site-specific cancers, this does suggest
a more advanced cancer at diagnosis, possibly indicative of delays in detection and diagnosis.
Interestingly, two studies examined the effect of age on the relationship between psychotic disorders
and cancer incidence. Both studies found a higher risk of cancer among people with psychotic disorders
that was more pronounced in the younger age categories (20-39 and 20-29).155,169
Finally, numerous studies have identified elevated mortality rates in people with psychotic
disorders following cancer diagnoses, relative to people without psychotic disorders. 170–176 A degree of
this elevated mortality is likely attributable to differences in treatment access and quality of care, and
exacerbated by other medical comorbidities.174,175,177 However, no studies to date have examined cancer
incidence, stage at diagnosis, and mortality within the same cohort.

2.5.1 Limitations of Included Studies
The risk of bias assessment identified several limitations to the studies included in this review,
such as issues regarding ensuring that cancer was not present at the start of each study, selection bias, and
inclusion of important confounding factors. For several included studies, there was no clear lookback
window or similar methods to exclude prevalent cases of cancer prior to the start of the study. Therefore,
it could not be ensured that studies were including incident cases of cancer, rather than prevalent or
recurrent cancer cases.
Most included studies used population-based health administrative data, however a number of
databases only included individuals eligible for a specific health insurance program and often only
represented a particular subset of the population, such as those with disability benefits or lower income –
as such, they are likely of lower socioeconomic status. Conversely, a number of studies included data from
private health insurance programs, which would include people who are likely employed and of higher
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socioeconomic status in countries. Therefore, the sampled populations are substantially heterogenous
across the included studies. Furthermore, included studies variably reported case definitions, limiting the
ability to assess the validity of these case definitions.
A majority of studies included in this review did not adequately control for important confounding
factors, either through matching or multivariable regression models, and many studies relied on indirect
standardization to control for age and sex. The etiology of cancer is complex, and consideration of a wide
range of environmental, lifestyle, and biological factors is important when evaluating cancer risk in any
population.
Additionally, a large proportion of studies did not report the extent of missing data within their
samples. Therefore, we are unable to account for how this may have influenced the results of individual
studies regarding incidence or stage at diagnosis.
Finally, our meta-analysis found evidence of a lower risk of skin cancer among people with
psychotic disorders. However, it should be noted that included studies had varying definitions of skin
cancer, with one study excluding non-melanoma skin cancer.178 Therefore, pooled estimates of skin cancer
risk may be unreliable. Additionally, some studies reported estimates of site-specific cancers with a small
number of outcome events, thereby creating extremely wide confidence intervals, often extending down
to zero.

2.5.2 Limitations of the Review
The findings of this review must be considered in light of its limitations. Firstly, the literature
search did not include grey literature or other unpublished studies, thereby excluding a body of potentially
relevant research and potentially introducing publication bias. Secondly, a high degree of statistical
heterogeneity was found in each of our meta-analyses. This is likely the result of the wide range of studies
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included in the meta-analysis. All effect measures of cancer risk which adjusted for age, at a minimum,
were assumed to approximate an age-adjusted risk ratio. Although this decision was made in order to
analyze a broader range of studies with varying methodology, this likely contributed to the observed
heterogeneity. A majority of the studies adjusted for age and sex, however a smaller number of studies
accounted for other confounding variables, so the estimates included in the meta-analysis have varying
amounts of residual confounding. Lastly, the power of the Egger’s test to detect publication bias across
studies reporting stage at diagnosis was limited by the smaller number of studies available for metaanalysis.138 Therefore, it is unclear whether publication bias was present in our examination of stage at
diagnosis.

2.6 Conclusions
This systematic review and meta-analysis identified no significant difference in overall cancer risk
among people with psychotic disorders; however, differences were found for specific cancer sites. These
differences are likely the products of antipsychotic medication exposure, environmental factors, and
biological factors—the effects of which need to be further investigated. People with psychotic disorders
have higher odds of metastases at diagnosis compared to people without psychotic disorders, suggesting
delayed detection and diagnosis. These disparities in access of treatment may be contributing to higher
mortality among patients with psychotic disorders.164,167,179–181 Programs which target cancer education,
screening, and early diagnosis among individuals with psychotic disorders may translate into better health
outcomes.
As informed by the findings of this review, there are a number of suggestions for future research
conducted in this area. Firstly, it is suggested that future research consider additional confounders, such
as obesity and related cardiometabolic comorbidities, in the relationship between psychotic disorder
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diagnoses and cancer risk. Secondly, we suggest that future research explore age and gender-related
differences in cancer incidence among people with psychotic disorders in order to understand how these
variables may modify this relationship. Lastly, it is suggested that future research aim to better elucidate
the interrelationships between incidence, stage at diagnosis, and treatment with mortality among people
with psychotic disorders.
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2.10 Tables and Figures
Table 2.1: Comparison of current meta-analysis with similar meta-analyses

Exposure of interest

Current meta-analysis

Catts et al., 2008

Li et al., 2018

Diagnosis with psychotic disorders

Diagnosis with schizophrenia, and

Diagnosis with schizophrenia

(affective and non-affective)

relatives of people diagnosed with
schizophrenia

Outcome of interest

•

•

•
Measures analyzed

Overall cancer incidence

•

Overall cancer incidence

•

Overall cancer incidence

(age-adjusted)

•

Site-specific cancer

•

Site-specific cancer incidence

Site-specific cancer

incidence for 6 common

incidence (age-adjusted)

sites

for 6 common sites

Stage at diagnosis

Multiple measures of incidence

Standardized incidence ratio (SIR)
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Multiple measures of incidence

Figure 2.1: PRISMA flowchart
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Table 2.2: Characteristics of studies included in qualitative synthesis
Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Ahlgrén-

Finland

A

non-affective

Rimpiläinen

psychotic

et al., 2020182

disorders

Arffman et

Finland

A

al., 2019176

non-affective

S

breast

Retrospective

Study

Sample

Period

Size (n)

1969 - 2013

78,079

cohort

Sample

group
Finnish Cancer

without

Registry

psychotic
disorders

S

lung

Retrospective

psychotic

1990 - 2013

34,572

cohort

Finnish Cancer

without

Registry

psychotic

disorders
Baillargeon

USA

A

unspecified

Comparison

disorders
S

colon

Retrospective

et al., 2011172

1993 - 2005

63,547

cohort

Surveillance,

without

Epidemiology,

psychotic

and End Results

disorders

Program
Barak et al.,

Israel

A

2005123

schizophrenia,

I

all cancer

bipolar

Retrospective

1993 - 2003

3,226

cohort

Inpatients at

general

Abarbanel

population

Mental Health
Center
Barak et al.,

Israel

A

schizophrenia

I

all cancer

2008154

Retrospective
cohort
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1960 - 2005

2,011

Inpatients at

general

Abarbanel

population

Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)

Study

Sample

Period

Size (n)

Sample

Comparison
group

Mental Health
Center
Bergamo et

USA

A

schizophrenia

S

all cancer

al., 2014183

Retrospective

1992 - 2009

96,702

cohort

Surveillance,

without

Epidemiology,

psychotic

and End Results

disorders

Program
Brink et al.,

Denmark

A

schizophrenia

I

all cancer

2019184

Retrospective

1980 - 2012

27,141

cohort

Danish National

without

Patient Register

psychotic
disorders

Chang et al.,
2013173

UK

A

schizophrenia,

S

all cancer

Clinical Record

without

Interactive

psychotic

disorder,

System (CRS)

disorders

schizoaffective

at South London

disorder

and Maudsley

bipolar

Retrospective
cohort

1999 - 2008

28,477

(SLAM) and
Biomedical
Research Centre
(BRC)
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Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Chen et al.,

Taiwan

A

schizophrenia

I

all cancer

2018153

Retrospective

Study

Sample

Period

Size (n)

2000 - 2010

32,731

cohort

Sample

Comparison
group

Psychiatric

general

Inpatient

population

Medical Claims
Database
Chou et al.,

Taiwan

A

schizophrenia

I

all cancer

2011171

Retrospective

2000 - 2008

237,413

cohort

National Health

general

Insurance

population

Research
Database
Chou et al.,

Taiwan

A

schizophrenia

I

breast

Retrospective

2017185

1998 - 2008

21,454

cohort

National Health

without

Insurance

psychotic

Research

disorders

Database
(NHIRD)
Cunningham

New

et al., 2015175

Zealand

A

schizophrenia,

S

all cancer

bipolar

Retrospective
cohort

disorder,
schizoaffective
disorder
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2006 - 2010

8,434

New Zealand

without

Ministry of

psychotic

Health

disorders

Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Dalton et al.,

Denmark

A

schizophrenia

I

all cancer

2005152

Retrospective

Study

Sample

Period

Size (n)

1969 - 1995

22,766

cohort

Sample

Comparison
group

Danish

general

Psychiatric

population

Central Register
Dalton et al.,

Denmark

A

2008186

schizophrenia

I

lung

Retrospective

and other

1994 - 2003

3,218,440

cohort

psychoses
Dalton et al.,

Denmark

A

2008187

schizophrenia

I

all cancer

and other

UK

A

schizophrenia

general

Registration

population

System
Retrospective

1994 - 2003

3,218,440

cohort

psychoses
Goldacre et

Danish Civil

Danish Civil

general

Registration

population

System
I

all cancer

al., 2005188

Retrospective

1963 - 1999

9,649

cohort

National Health

general

Service

population

Hospitals
Database
Grinshpoon

Israel

A

schizophrenia

I

all cancer

et al., 2005151

Retrospective
cohort

1962 - 2001

33,372

Israeli

general

Psychiatric Case

population

Register
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Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Hippisley-

UK

A

Cox et al.,

schizophrenia,

I

bipolar

2007189

breast, colon,

Retrospective

rectal,

cohort

Study

Sample

Period

Size (n)

1995 - 2005

4,040,494

Sample

Comparison
group

QRESEARCH

without

database

psychotic

gastroesophageal,

disorders

prostate, and
respiratory
Ishikawa et

Japan

A

schizophrenia

S

gastric, colorectal

al., 2016170

Retrospective

2010 - 2013

12,475

cohort

Japanese

without

Diagnosis

psychotic

Procedure

disorders

Combination
database
Ji et al.,

Sweden

A

schizophrenia

I

all cancer

20138

Retrospective

1965 - 2008

59,233

cohort

Swedish

general

Hospital

population

Discharge
Register
Kisley et al.,
2013174

Australia

A

schizophrenia,

I

all cancer

affective

Retrospective
cohort

psychosis,

1988 - 2007

135,451

Western

general

Australia Data

population

Linkage System
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Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)

Study

Sample

Period

Size (n)

2002 - 2007

93,271

Sample

Comparison
group

other
psychoses
Kisley et al.,

Australia

A

2016135

Lawrence et

schizophrenia,

I

all cancer

affective

Australia

A

al., 2000177

Retrospective
cohort

Queensland

general

Hospital

population

psychosis,

Admitted

other

Patients’ Data

psychoses

Collection

schizophrenia,

I

all cancer

affective

Retrospective

1982 - 1995

172,932

cohort

psychosis,

Western

general

Australia Data

population

Linkage System

other
psychoses
Levav et al.,

Israel

A

schizophrenia

I

all cancer

20079

Retrospective

1960 - 2003

6,132

cohort

Israeli

general

Psychiatric Case

population

Register
Levav et al.,

Israel

A

schizoaffective

I

all cancer

2009190

Retrospective
cohort

1980 - 2005

2,400

Israeli

general

Psychiatric Case

population

Register
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Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Liao et al.,

Taiwan

A

schizophrenia

I

liver

Retrospective

2015169

Study

Sample

Period

Size (n)

1998 - 2010

11,965

cohort

Sample

Comparison
group

National Health

without

Insurance

psychotic

Research

disorders

Database
Lichtermann

Finland

A

et al., 20017

schizophrenia,

I

all cancer

schizoaffective

Retrospective

1969 - 1996

26,996

cohort

disorder

National

general

Hospital

population

Discharge
Register,
National
Disability
Pension
Register

Lin et al.,

Taiwan

A

schizophrenia

I

all cancer

2013155

Retrospective

1995 - 2007

102,202

cohort

National Health

general

Insurance

population

Research
Database
Lin et al.,
2013136

Taiwan

A

schizophrenia,

I

all cancer

bipolar

Retrospective
cohort
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1995 - 2009

91,884

National Health

general

Insurance

population

Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)

Study

Sample

Period

Size (n)

Sample

Comparison
group

Research
Database
Manderbacka

Finland

A

unspecified

S

all cancer

et al., 2017191

Retrospective

1990 - 2013

600,052

cohort

Finnish Cancer

without

Registry

psychotic
disorders

McGinty et

USA

A

al., 2012178

schizophrenia,

I

bipolar

all except non-

Retrospective

melanoma skin

cohort

1996 - 2004

3,317

cancer
Mortensen et

Denmark

A

schizophrenia

I

all cancer

al., 1989192

Maryland

general

Medicaid

population

Program
Retrospective

1957 - 1984

6,152

cohort

Inpatients at

general

Danish

population

psychiatric
hospitals
Mortensen,

Denmark

A

schizophrenia

I

all cancer

1994193

Retrospective

1970 - 1988

9,156

cohort

Danish

general

Psychiatric Case

population

Register
Osborn et al.,
2013194

UK

A

schizophrenia,

I

all cancer

schizoaffective,

Retrospective
cohort

bipolar,

1990 - 2008

136,784

The Health

without

Improvement

psychotic
disorders
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Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)

Study

Sample

Period

Size (n)

Sample

Comparison
group

affective

Network

psychosis, brief

Database

psychoses,
psychoses
NOS
Pettersson et

Sweden

A

schizophrenia

I

all cancer

al., 2020150
Raviv et al.,

Retrospective

1990 - 2013

111,306

cohort
Israel

A

schizophrenia

I

all cancer

2014195

Retrospective

1990 - 2011

4,326

cohort

National Patient

general

Register

population

Inpatients at

general

Abarbanel

population

Mental Health
Center
Scheflen,
1951196

USA

C

schizophrenia,

I

lung

Case-control

Inpatients at

general

bipolar,

Worcester State

population

affective

Hospital

psychosis, nonorganic
psychosis
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1928 - 1942

NR

Citation

Country

Data

Psychotic

Outcomes

Cancer sites

Study Design

disorder(s)
Toender et

Denmark

A

al., 2018168

schizophrenia,

I, S

all cancer

Sample

Period

Size (n)

1978 - 2012

579,039

Sample

Comparison
group

Danish Civil

without

Registration

psychotic

System

disorders

Integro (general

without

practice

psychotic

psychosis,

registration

disorders

other

network)

bipolar

Retrospective

Study

cohort

disorder,
schizoaffective
disorder
Truyers et al.,
2011197

Belgium

A

schizophrenia,

I

all cancer

affective

Retrospective
cohort

psychoses

A = Administrative, C = Clinical, I = incidence, S = stage at diagnosis
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1997 - 2007

4,904

Figure 2.2: Risk of bias assessment summary
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Figure 2.3: Forest plot of meta-analysis of age-adjusted incidence of cancer in people with psychotic disorders, relative to the general
population, sub-grouped by psychiatric diagnosis
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Figure 2.4: Forest plot of site-specific cancer incidence in people with PD, relative to the general population
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Figure 2.5: Forest plot of meta-analysis of odds of metastases in people with psychotic disorders, relative to the general
population.
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Figure 2.6: Forest plot of meta-analysis of odds of metastases in people with psychotic disorders, relative to the general

Chapter 3
3 Cancer incidence and stage at diagnosis among people
with recent-onset psychotic disorders: A retrospective
cohort study using Ontario health administrative data

3.1 Abstract
Background: Prior evidence on the incidence of cancer in people with psychotic disorders,
compared to the general population, is equivocal, although those with psychotic disorders so have
more advanced stage of cancer at the time of diagnosis. The objective of this study was to compare
cancer incidence and stage at diagnosis for people with psychotic disorders, relative to the general
population.
Methods: We used a retrospective cohort design to identify people with non-affective psychotic
disorders diagnosed between 1995 and 2004, and a comparison group from the general population
through linkage of Ontario health administrative databases held by the Institute for Clinical
Evaluative Sciences (ICES). The cohort was followed until the end of 2019 for incident cases of
cancer. We compared cancer incidence and stage at diagnosis between people with psychotic
disorders and those without.
Results: People with psychotic disorders had an 8.6% higher incidence (IRR = 1.09, 95%CI: 1.05
to 1.12) of cancer overall, relative to the comparison group, adjusting for potential confounding
factors. The incidence risk specific to individual cancer sites varied among people with psychotic
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disorders, compared to those without. People with psychotic disorders had 23% greater odds (OR
= 1.23, 95% CI: 1.13, 1.34) of being diagnosed with higher stage cancer, compared to those without
psychosis.
Conclusions: This study found an elevated incidence of cancer in people with non-affective
psychotic disorder, relative to the general population, with significant effect modification by sex.
Additionally, we identified higher odds of more advanced stage at diagnosis in people with
psychotic disorders, indicative of a significant diagnostic delay and a need to increase education
and targeted access to care. Future research should examine the confounding effects of lifestyle
factors and anti-psychotic medication, as well as potentially intermediary effects of
cardiometabolic disorders.

3.2 Introduction
People with psychotic disorders – which can include schizophrenia, bipolar disorder, and
depression with psychotic features – have mortality rates up to three times higher than the general
population,18,19,21 translating to a 15-year reduction in life expectancy.22 It is estimated that 59%
of this excess mortality is attributable to differences in concurrent medical illnesses.128 Prior
research suggests that people with psychotic disorders have a significantly higher incidence of at
least 19 different medical illnesses, relative to the general population, which include liver disease,
renal disease, diabetes, congestive heart failure, and myocardial infarction.19 These concurrent
medical comorbidities have been extensively researched, with particular focus on cardiometabolic
disorders.55,198,199
This attention towards physical comorbidities among people with psychotic disorders has
also led to a growing number of studies on cancer risk; however, this relationship presents an area
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of significant controversy..129,130 Prior evidence on the incidence of cancer in people with psychotic
disorders, compared to the general population, is equivocal. A number of studies have found an
elevated incidence of cancer among those with psychotic disorders,7,124,187,189 whereas others have
found a lower incidence.123,171,193 The apparent lower incidence of cancer among people with
psychosis was first noted in the Report of the Commissioners in Lunacy in 1909. 121 Since then, a
series of hypotheses have been put forth as explanations for the lower incidence observed in many
studies. These hypotheses include elevated natural killer cell activity, the protective effect of
excess dopamine, an elevated rate of apoptosis, and the interaction of antipsychotic medication
with cytochrome enzyme activity.188 However, many of these hypotheses do not account for the
wider range of behavioural and lifestyle factors affecting cancer risk,129 which differ in prevalence
between patients with psychotic disorders and the general population, thereby producing
differences in site-specific cancers.129
Prior meta-analyses of the incidence of site-specific cancers in people with schizophrenia
have found lower risk of prostate cancer, melanoma, and colorectal cancer, as well as higher
incidence of breast, cervical, and uterine cancers.1,2,131,200,201 Results of the cohort studies were
found to vary significantly, depending on age of participants and duration of follow-up—two
variables which are inconsistently reported. Furthermore, previous research has found the effect
of psychotic disorder on cancer incidence to vary significantly across age categories and sex,
suggesting effect modification, whereby females with psychotic disorders had a higher incidence
of cancer compared to females without psychotic disorders and no difference was found for males
with psychotic disorders.150,155 Prior research has also found that people with serious mental
illnesses (SMI), including psychotic disorders, are more likely to have more advanced stage of
cancer at the time of diagnosis, suggesting disparities in prevention and treatment seeking
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behaviour and access to care. A meta-analysis found that those with prior diagnoses of SMI had
higher odds of advanced stage at diagnosis, higher odds of presenting with metastases, and worse
survival, compared to those without SMI.6 Psychotic disorders were also found to be associated
with 60% increased risk of cancer-specific mortality.
There still remains significant debate regarding whether people with psychotic disorders
have an elevated incidence of cancer compared to the general population. Furthermore, current
evidence on stage-at-diagnosis is limited by a variety of methodological shortcomings and
inconsistencies. Although studies examining cancer mortality and stage at diagnosis have been
done in Canada,3,202 there have been no Canadian studies to date on the incidence of cancer among
people with psychotic disorders. Provincial health administrative data in the Canadian public
healthcare system provides an opportunity to obtain population-based data on cancer incidence
and stage at diagnosis in people with psychotic disorders.
The objective of this study was to use Ontario health administrative data to examine cancer
incidence following the first diagnosis of non-affective psychotic disorder, relative to a general
population comparison group. As a secondary objective, we also sought to compare stage at
diagnosis for people with psychotic disorder and the general population. We hypothesized that we
would observe significant heterogeneity of cancer incidence in people with NAPD, relative to
those without NAPD by cancer site. Additionally, we hypothesized that people with NAPD would
have greater odds of higher stage cancer at diagnosis.
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3.3 Methods
3.3.1 Data sources
We followed the RECORD reporting guidelines for observational studies using health
administrative data (Appendix A1).203 The current study used population-based health
administrative databases from Ontario, Canada, held by ICES (formerly known as the Institute for
Clinical Evaluative Sciences). The following databases were linked using unique encoded
identifiers and analyzed at ICES:
•

The Registered Persons Database (RPDB) contains socio-demographic data for all Ontario
residents registered for the Ontario Health Insurance Plan (OHIP). 204 Information in the RPDB
includes date of birth, residential information, and dates of last contact with the healthcare
system.204

•

The Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) contains
data regarding separations from acute care, including discharges, deaths, sign-outs, and transfers,
which are collected directly from acute care facilities and public health departments. 205 Each
abstract contains data pertaining to hospital activity for each separation, including diagnostic,
intervention, patient demographic, and administrative information.205

•

The National Ambulatory Care Reporting System (NACRS) is a database created by CIHI for the
purposes of capturing information regarding client visits to facility and community-based
ambulatory care.206 NACRS contains demographic, clinical, administrative, financial, and servicespecific information for emergency department visits, day surgery procedures, diagnostic imaging,
and clinic visits.206

•

The OHIP Claims Database contains fee-for-service claims, as well as non-fee-associated (shadow
billing) claims for physicians working under other payment models, submitted by physicians for
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health services provided to Ontario residents under OHIP.204 For each claim, information regarding
date and location of service, type of service provider, diagnosis, and a service fee code is
provided.207 OHIP covers approximately 97% of all Ontario residents.208
•

The Ontario Cancer Registry (OCR) compiles data on all cases of cancer diagnosed among Ontario
residents.209 This registry allows accurate reporting of cancer incidence, prevalence, and mortality.
This reporting is facilitated through the compilation of data from the CIHI DAD and National
Ambulatory Care Reporting System (NACRS) databases, as well data from regional cancer
centres, pathology reports, death certificates, and out-of-province cancer diagnoses.

•

The Primary Care Population dataset (PCPOP) includes all Ontario residents who have had contact
with health services within any 7 to 9 year period, starting in the year 2000.210 The PCPOP contains
data on demographics, primary care, attachment status, and a number of variables specific to
contact with healthcare services.210

• The ICES Physician Database (IPDB) contains demographic, specialty, and other information
about physicians practicing in the province of Ontario.211

3.3.2 Study Design and Inclusion Criteria
We used a retrospective cohort design to identify people aged 14 to 59 at their index
diagnosis of non-affective psychotic disorder, diagnosed between January 1995 and December
2004,212 which formed our exposed group. To be classified as a case of psychotic disorder, people
must have met at least one of the following criteria: (1) a primary discharge diagnosis of
schizophrenia, schizoaffective disorder, or psychosis not otherwise specified (NOS) from an
inpatient hospitalization (International Classification of Diseases, 9 th Revision [ICD-9] code 295.x
or 298.x; ICD-10 codes F20, F25, or F29) or (2) at least two OHIP billing claims or emergency
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department visits with a diagnostic code for schizophrenia or schizoaffective disorder (ICD-9 code
295.x or 298.x; ICD-10 codes F20, F25, or F29) within a 24-month period. Psychosis NOS,
replaced by “unspecified schizophrenia spectrum and other psychotic disorders” describes
symptoms resulting in functional impairment and distress, characteristic of schizophrenia
spectrum disorder while not meeting the full criteria of another condition.213 In practice, this
diagnosis is also applied to presentations which do not provide adequate information for a specific
diagnosis.213 This algorithm has been validated against medical chart diagnoses, and was found to
have sensitivity of 93.9%, a specificity of 50.0%, a positive predictive value of 62.1%, and a
negative predictive value of 90.4% for a diagnosis of schizophrenia, schizoaffective disorder, or
psychosis NOS.212 Diagnosis of affective psychoses requires four-digit ICD-10 codes, which are
only available through emergency department and hospitalization billings, and are not available in
OHIP billings. Therefore, for the purposes of maintaining external validity, we restricted our case
definition to non-affective psychotic disorders.
The index event was defined as diagnosis with non-affective psychotic disorder, restricted
to the first eligible date identified over the accrual period. A lookback window of five years prior
to the index date for each person was used to identify and exclude chronic cases of psychosis. We
selected the ten-year accrual period in order to accommodate a lookback window stretching back
to 1990, the earliest date which we could collect billing data. We identified an unexposed group
of people who had not previously received a diagnosis of non-affective psychotic disorder,
frequency matched by age and sex at a ratio of 4:1. Index dates matched to the exposed group were
assigned at random to the unexposed group. People were excluded from the comparison group if
there was any evidence of schizophrenia, schizoaffective disorder, or psychosis NOS in the 5 years
prior to the index date.
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People were excluded from the study if they were under the age of 14 or over the age of 59
at the index date. This age range was chosen due to the low incidence of psychotic disorders prior
to age 14, and to exclude possible cases of dementia after age 60. Non-residents of Ontario and
those not eligible for OHIP in the year prior to the index date were excluded to improve continuity
and completeness of data. Finally, we also excluded people who had been diagnosed with cancer
prior to the index date.

3.3.3 Outcomes
Incident cases of cancer occurring after the index date were identified via linkage to the
OCR. The cohort was followed until the end of the follow-up period (December 2019), death, or
a new onset of non-affective psychotic disorder in the unexposed group, at which point censoring
occurred among non-cases.
A detailed description of the derivation of the outcome variables can be found in Appendix
A2. The primary outcome of this study was the time from the index date to the first date of cancer
diagnosis, determined by the diagnosis date of the first appearance of an ICES Key Number (IKN)
in the OCR. For this diagnosis, data pertaining to the stage and topography of the primary tumour
were collected. Stage at diagnosis was classified using the Tumour, Node, and Metastases (TNM)
stage at the first available primary site for that person. TNM staging is then grouped into stages I
through IV.71 Stage I describes a localized tumour which has not penetrated nearby tissues. 71
Stages II and III denote regional spread of the tumour to nearby tissues and lymph nodes.71 Stage
IV indicates that cancer has metastasized and spread to distant tissues in the body. 71 We did not
include stage 0 tumors as part of our outcome definition, as these represent pre-cancerous lesions.
The cancer site was based on ICD-O-3 topography codes for the primary tumor site, and grouped
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into the following sites: bladder, brain, breast, cervical, colorectal, esophageal, Hodgkin’s
lymphoma, kidney, larynx, leukemia, liver, lung, melanoma, myeloma, non-Hodgkin’s lymphoma,
oral cavity, ovary, pancreas, prostate, stomach, testis, thyroid, uterus, and other.

3.3.4 Other Variables
The following confounding variables, with demonstrated associations with cancer
incidence, were controlled for in the analyses: age, sex, neighborhood-level income quintile,
rurality of residence, and access to a family physician. All confounding variables were assessed at
baseline.120,214–216 Age and sex were obtained from the RPDB, and age was used as a continuous
variable. Neighborhood-level income quintile was obtained from the RPDB and was based on the
average household income for each postal code, computed using census data. Rurality was defined
using the Rurality Index of Ontario. Access to a family physician was based on whether a person
was assigned to a family physician as of the index date, defined using the PCPOP database.

3.3.5 Statistical Analyses
We summarized descriptive characteristics of the cohort using frequency tables and
calculated standardized differences to compare baseline characteristics between the exposed and
unexposed groups. Standardized differences greater than 10% are indicative of significant
between-group differences.217
The primary objective of this study was to compare the incidence of cancer between people
with psychotic disorders and the general population comparison group. We presented the crude
incidence rates of all cancer, as well as site-specific cancer for the exposed and unexposed group.
We used univariate and multivariable Poisson regression models to compare the time from the
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index date to the first cancer diagnosis among people with psychotic disorders and those in the
comparison group. We adjusted for age, sex, neighbourhood income quintile, access to a family
physician, and rurality of residence. Although the comparison group was frequency matched by
age and sex during the cohort build, age and sex were also included in the multivariable analysis
to adjust for residual confounding. We also conducted post-hoc stratified analyses by age group
and sex, as previous research has suggested that age and sex act as effect modifiers in the
relationship between schizophrenia and overall cancer risk.150
Additionally, we ran separate Poisson regression models for the incidence of cancer at each
specific site. Those who developed cancer at sites other than the site of interest were censored at
the time of that cancer diagnosis. Analyses of sex-specific cancers – including cervical, ovarian,
uterine, testicular, and prostate cancer – were restricted to their respective sex. Additionally, breast
cancer was treated as a sex-specific cancer occurring in females, as males account for only 1% of
all breast cancer case,218 however sensitivity analyses were performed to examine the effect of
including males in the analysis of breast cancer incidence.
To examine the influence of sex-specific cancers on the overall incidence of cancer in
people with psychotic disorders, we performed post-hoc sensitivity analyses by excluding sexspecific cancers from the model of overall cancer incidence, including breast, cervical, uterine,
ovarian, prostate, and testicular cancer.
Our secondary objective was to compare stage at diagnosis between people with psychosis
who developed cancer, and those who developed cancer in the comparison group. A proportional
odds model for stage at diagnosis was fit on the binary variable of psychotic disorder diagnosis,
adjusting for age, sex, neighbourhood income quintile, access to a family physician, and cancer
site. Cancer site was included as a potential confounding factor to control for the varying
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aggressiveness of cancer at different sites, which would influence the likelihood of presenting with
more or less advanced staging at diagnosis.219,220 People with missing data on stage at diagnosis
were excluded from this analysis.
We found a large proportion of missing data on stage at cancer diagnosis; therefore, we
performed a post-hoc analysis to examine whether people with psychotic disorders had higher odds
of having missing data. A logistic regression model of missing stage at diagnosis was fit on the
binary variable of diagnosis with psychotic disorder, adjusting for age, sex, neighbourhood income
quintile, access to family physician, and cancer site.
All statistical analyses were performed using STATA v16, and results are presented as
incidence rate ratios (IRR) or odds ratios (OR), with corresponding 95% confidence intervals (CI).

3.4 Results
We identified 63,410 cases of non-affective psychotic disorder between 1995 and 2004
who met the study inclusion criteria, and these cases were frequency matched on age and sex to
260,539 people from the general population. A complete breakdown of the derivation of the study
cohort can be found in Appendix A3.
The characteristics of the study cohort at the index date are presented in Table 1. The mean
age for both groups was 36.0 years (SD = 11.9), and 45% of the sample were females. As the
comparison group was sampled from the general population, there was an even distribution across
the neighborhood-level income quintiles, whereas a higher proportion of people in the exposed
group were in the lowest neighborhood-level income quintile (31%). Similar proportions of the
exposed group (13%) and comparison group (10%) lived in rural areas. Eighty-nine percent of
people in the exposed group had access to a family physician, compared to 84% in the comparison
59

group. With respect to psychiatric diagnoses among the exposed group, 60% had an index
diagnosis of schizophrenia spectrum disorder and 40% had an index diagnosis of psychosis NOS.

3.4.1 Incidence
The total observation time among the unexposed group was 1,814 billion person-years with
a mean observation time of 19 years. The total observation time among the exposed group was
425.4 million person-years and the mean observation time was 18 years. Over the follow-up
period, a total of 5,069 people with psychotic disorder developed cancer, for an incidence rate of
4.5 cases per 1,000 person-years. In the unexposed group, 20,175 people developed cancer for a
rate of 4.2 cases per 1,000 person-years. People with psychotic disorder had an 8.6% higher
incidence (IRR = 1.09, 95% CI: 1.05 to 1.12) of cancer overall, relative to the comparison group,
adjusting for age, sex, income, rurality of residence, and access to a family physician (Table 2).
The results of the Poisson regression models for site-specific cancers can be found in Table
2. People with psychotic disorder had a higher incidence of breast cancer (IRR = 1.09, 95% CI:
1.01 to 1.17), cervical cancer (IRR = 1.43, 95% CI: 1.10 to 1.87), esophageal cancer (IRR = 1.72,
95% CI: 1.29 to 2.29), leukemia (IRR = 1.23, 95% CI: 1.08 to 1.40), liver cancer (IRR = 1.70,
95% CI: 1.31 to 2.21), lung cancer (IRR = 1.52, 95% CI: 1.40 to 1.65), and uterine cancer (IRR =
1.19, 95% CI: 1.02 to 1.38). People with psychotic disorder had a lower incidence of melanoma
(IRR = 0.66, 95% CI: 0.55 to 0.79), thyroid cancer (IRR = 0.84, 95% CI: 0.72 to 0.98), and prostate
cancer (IRR = 0.59, 95% CI: 0.53 to 0.66). Including males in the analysis of breast cancer
incidence did not significantly alter results.
The results of the post-hoc stratified analyses by age and sex can be found in Appendix
A4. Sex was found to be an effect modifier on the association between psychotic disorders and
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incidence of cancer. Females with psychotic disorder had a higher incidence of cancer overall,
compared to females without psychosis (IRR = 1.15, 95% CI: 1.11 to 1.20), adjusting for age,
income, rurality of residence, and access to a family physician. Exclusion of female-specific
cancers, including breast, cervical, uterine, and ovarian cancer, did not significantly alter the
estimate. In contrast, there was no difference in cancer incidence for males with psychotic disorder,
compared to males without, adjusting for age, income, rurality of residence, and access to a family
physician. Removal of male-specific cancers, testicular and prostate cancer, produced an IRR
indicating an increased incidence of remaining cancers in males with psychotic disorders,
compared to those without (IRR = 1.14, 95% CI: 1.08 to 1.20). No significant differences were
found in the IRR by age category for either males or females.

3.4.2 Stage at Diagnosis
The frequencies and percentages of people diagnosed with each stage can be found in table
3. The results of the proportional odds model of stage at diagnosis and the logistic regression model
of missing stage at diagnosis can be found in table 4. More than half of people diagnosed with
cancer had unknown stage at diagnosis (exposed group: 56%; unexposed group: 51%) and were
excluded from the analysis. People with psychotic disorder had 23% greater odds (OR = 1.23, 95%
CI: 1.13, 1.34) of being diagnosed with higher stage cancer, compared to those without psychosis.
Our post-hoc analysis suggests that people with psychotic disorder also had 24% greater odds (OR
= 1.24; 95% CI: 1.17 to 1.32) of missing stage at diagnosis data, relative to those in the comparison
group.
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3.5 Discussion
This study identified a higher incidence of cancer in people with non-affective psychotic
disorders, relative to the general population, with substantial variation by cancer site. We also
found that people with psychotic disorder had a more advanced stage at diagnosis. Our findings
are strengthened by the use of a population-based health administrative dataset in a country with
universal healthcare, which allows for a large, representative sample in a county with a publicly
funded universal health care system. Furthermore, the use of health administrative data allowed
for a longer follow-up period, and the present study represents one of few longitudinal studies to
examine both incidence and stage at diagnosis within the same cohort.
Previous meta-analyses have produced conflicting results regarding excess risk of cancer
among people with psychotic disorders, with one finding a lower incidence of cancer,2 and two
showing no difference in incidence between people with psychotic disorder and the general
population.1,201 However, these prior meta-analyses have found heterogeneity in both the direction
and magnitude of effect by cancer site,1,2,201 which is similar to the findings from the current study.
It is possible that the small but significantly elevated risk of cancer overall that we observed among
people with psychotic disorders is driven by higher rates of more common cancers in this
population, such as breast cancer, colorectal cancer, and lung cancer.
The present study identified significant effect modification in overall cancer risk by sex.
Similar to previous studies, we found that females with psychotic disorders had a significantly
higher incidence of cancer, compared to females without psychosis,150,155 which was not driven by
a higher risk of female-specific cancers. In contrast, we did not find a difference in cancer risk
between males with psychotic disorder and those without;150,155 however, after excluding prostate
cancer, males with psychotic disorder were found to be at a higher risk of cancer overall, similar
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to the IRR observed in females with psychotic disorder. Similar patterns were observed in previous
studies, where removing prostate cancer led to an excess risk of cancer overall in males with
psychotic disorder, compared to men without.150,155
It was initially hypothesized that people with psychotic disorders have a lower incidence
of cancer.121 One theory posits that genetic factors associated with schizophrenia decrease the risk
of developing cancer.8 It has been suggested that polymorphisms of Tp53 increase neuronal
apoptosis during embryonic development, which is associated with both the development of
schizophrenia as well as greater regulation of tumorigenesis, thereby reducing the risk of
developing cancer.221 A number of studies have identified an association between Tp53
polymorphisms and schizophrenia.222–224 Furthermore, several cohort studies have examined
cancer risk in the siblings and parents of people with schizophrenia,7–9,225 with a meta-analysis of
these data showing a lower risk of all site cancer in close relatives of people with schizophrenia,
despite finding no difference in cancer risk for people with schizophrenia. 1 Opponents of this
theory have argued that in addition to cohort studies producing inconsistent results, there are too
many unknown factors influencing cancer risk in this population which must be accounted for. 226
However, it is possible that the protective effects conferred by genetics are overcome by exposure
to environmental and lifestyle factors among people with psychotic disorders, 227 thus explaining
the lower incidence of cancer in relatives of people with schizophrenia, and the similar risk of
cancer among people with schizophrenia, relative to the general population.
Smoking has a demonstrated causal association with lung, bladder, and head/neck
cancers.66,67,96,97 Despite higher rates of smoking among people with psychotic disorder, prior
research has produced mixed results regarding lung cancer risk; however, adjustment for smoking
has been shown to attenuate the relative risk of lung cancer in people with psychosis. 1,2,127,201 The
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present study identified an elevated risk of lung cancer among people with psychotic disorder and
no difference for the incidence of bladder cancer, consistent with previous research.1,2,201 However,
our interpretation of these results is limited, given that we are unable to adjust for smoking or other
environmental exposures.
Additionally, people with psychotic disorders are more likely to have poor eating habits
and a sedentary lifestyle, resulting in higher rates of cardiometabolic disorders, including
cardiovascular disease, obesity, and diabetes,5,24,44–48 all of which have demonstrated associations
with breast and colorectal cancer.104,105 The present study identified a higher incidence of
colorectal cancer among people with psychotic disorders, inconsistent with the results of prior
meta-analyses; however, the 95% CI included 1, indicating the possibility of a null effect. 2,201
Additionally, diabetes mellitus is associated with a lower risk of prostate cancer.162 This
inverse association is thought to be the product of lower levels of testosterone, low responsiveness
to insulin, as well as downregulation of insulin growth factors.162 Therefore, higher risk of diabetes
among males with psychotic disorders may lead to a lower risk of prostate cancer. In agreement
with prior meta-analyses, the present cohort study identified a lower incidence of prostate cancer
among males with psychotic disorders.1,2,201
The risk of these cardiometabolic disorders is further exacerbated by treatment with
antipsychotic medications, with a significantly greater effect on females, compared to males. 28,29
Additionally, anti-psychotic medications (dopamine antagonists) have demonstrated highly
heterogenous effects on oncogenesis depending on cancer site, increasing the risk of liver, breast,
and uterine cancer, while decreasing the risk of prostate cancer, 144,146–148,157 which is consistent
with our findings and with previous literature. 1,2,126,131,200,201 It has been proposed that
hyperprolactinemia resulting from antipsychotic medication is responsible for the higher risk of

64

breast and uterine cancer among females with PD and a lower incidence of prostate cancer among
males with PD, all of which are hormonally sensitive. 146–148 Males with schizophrenia who are
prescribed phenothiazines have also been found to have markedly lower prostate cancer
incidence.157
Additionally, people with schizophrenia spectrum disorders have three times the odds of
having hepatitis B (HBV) or hepatitis C (HCV) infections compared to those without.228 Globally,
it is estimated that 78% of all hepatocellular carcinoma is attributable to infection with HBV and
HCV.229 The increased prevalence of HBV and HCV infection among people with psychotic
disorders is largely driven largely by injection drug use and risky sexual behaviour.230
Furthermore, people with serious mental illnesses have been found to have low rates of vaccination
for hepatitis.231
We observed a higher odds of advanced stage at diagnosis in people with psychotic
disorders, which is also consistent with a prior meta-analysis, which found that in countries with
universal healthcare, people with mental illnesses had higher odds of advanced stage cancer at
diagnosis.6 This has also been shown for psychotic disorders specifically.201 These trends may be
indicative of a diagnostic delay due to disparities in healthcare-seeking behaviour and access to
screening and treatment.6,201 It has been previously shown that people with schizophrenia are less
likely to participate in screening for breast, cervical, prostate, and colorectal cancer. 164,167,179–181
Lower screening uptake may have variable impacts on cancer incidence, depending on the
effectiveness of cancer screening programs. In Canada and the USA, successful initiatives for papsmears and colorectal cancer screening – both of which allow for early detection and removal of
pre-cancerous lesions – have translated into dramatic reductions in cervical cancer and colorectal
cancer over time, as well as reduced mortality.77,80–82,232 On the other hand, significant increases
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in prostate and mammography screening have increased the observed incidence of prostate and
breast cancer, mainly through overdiagnosis, resulting in unnecessary treatment and little
difference in mortality.83–85,232,233 Therefore, low uptake of screening among people with psychotic
disorders, restricting their ability to benefit from these programs, may explain the higher incidence
of cervical and colorectal cancer, while significantly underestimating the incidence of prostate and
breast cancer in people, relative to the trends in the general population.126,155,234
Furthermore, while evidence regarding melanoma screening uptake among people with
psychotic disorders is limited, it is likely the pattern of lower screening uptake for other cancers
applies, thereby potentially reducing the observed incidence of melanoma among people with
psychotic disorders.150,235 It has been previously suggested that the observed reduced incidence of
melanoma among people with psychotic disorders is the result of reduced sun exposure; however,
there is limited evidence to support this theory.1
Important to the discussion regarding stage at diagnosis is the availability of accurate
staging data. A large proportion of people who developed cancer in the present study had an
unknown stage at diagnosis, and people with psychotic disorder had higher odds of having an
unknown stage at diagnosis, which has been shown previously.3,172 This demonstrates that patients
with psychotic disorders may not have had adequate staging performed, resulting from either lack
of access or refusal of services. In turn, this may limit the availability of diagnostic information
pertinent to informing cancer treatment and prognosis among people with psychotic disorders. It
is important to note that these differences persist in studies like this one, conducted in countries
with a universal healthcare system,3,170,172,191 suggesting that cost remains only one of many factors
influencing access to care for marginalized populations, such as people with psychotic disorders.
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Some of the trends we observed may be due to diagnostic overshadowing, whereby
physical symptoms reported by a person with mental illnesses are misattributed to the mental
illness by clinicians.236 People with psychotic disorders have a higher prevalence of
cardiometabolic disorders, viral infections, musculoskeletal diseases, sexual dysfunction, and
pregnancy complications, which are often dismissed or attributed to the psychiatric diagnosis,
consequently making them less likely to receive specialized treatment and screening for these
conditions.237 It is possible that a similar dismissal of symptoms in relation to malignancy may
contribute to delayed diagnosis and intervention.

3.5.1 Limitations
We are limited by the data available in the ICES databases; therefore, we were unable to
adjust for important confounding variables, such as smoking, obesity, antipsychotic medication
exposure, and a number of other lifestyle factors with known associations with cancer risk.1,5,24,44–
48,144

The case definition that we used to identify people with psychotic disorder has high

sensitivity, which increases the potential for false positives, and some people in our exposed group
may be misclassified, although we expect this to be nondifferential. Additionally, the cancer
registry used to define our outcome does not include cases of basal and squamous cell carcinomas
of the skin,238 which limits our ability to draw conclusions about some cancer types.238
Furthermore, the incidence of certain cancers, including Hodgkin’s lymphoma, laryngeal cancer,
and myeloma, were particularly low, thereby limiting the validity of our estimates for those
particular cancers.
As previously mentioned, there was a large proportion of missing data for stage at diagnosis
for people who developed cancer during the follow-up period. This may limit the generalizability
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of the findings if people with missing data differ systematically from those with available data on
stage at diagnosis, and our post hoc analyses do suggest that people with psychotic disorders are
more likely to have missing stage data. Moreover, low rates of cancer screening in people with
psychotic disorders may have resulted in detection bias for some types of cancer, such as breast
and prostate cancer.164,167,179–181
Finally, our cohort was restricted to people aged 15 to 59 at their respective index dates.
Therefore, the conclusions drawn from our analyses are limited to those within this age range and
may differ for elderly people with psychotic disorders. This age restriction may limit our
conclusions to those cancers which commonly occur in younger people including, brain, breast,
cervical, colorectal, leukemia, lymphoma, melanoma, testicular, and thyroid.239

3.6 Conclusions
This retrospective cohort study identified a small but significantly elevated incidence of
cancer in people with non-affective psychotic disorder, relative to the general population; however,
both the direction and magnitude of effect varied significantly by cancer site. Furthermore, we
identified effect modification by sex. We also found evidence of more advanced stage at diagnosis
in people with psychotic disorders, potentially indicative of diagnostic delay. Further efforts
should be made to improve the quality and granularity of population-based health administrative
data, such that future cohort studies may control for lifestyle factors such as smoking, obesity,
diabetes, and medication use. Future research should aim to evaluate the effects of a broader array
of confounding factors involved in cancer incidence and stage at diagnosis, as well as potential
intermediary effects of antipsychotic medication and cardiometabolic comorbidities. Lastly,
efforts should be made to improve education surrounding cancer screening and diagnosis targeting
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this population, as well as programs which improve access to care and increasing uptake of
vaccinations for HPV and hepatitis among people with psychotic disorders.
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3.8 Tables and Figures
Table 3.1: Descriptive characteristics of exposed and unexposed groups at the index date

Exposed

Unexposed

n (%)

n (%)

(N = 63,410)

(N = 250,539)

Characteristic

Age (years)

mean

Standardized
Difference (%)

36.0 (11.9)

36.01 (11.9)

0.1

15 – 20

6,090 (9.6)

24,010 (9.6)

0.1

20 – 29

14,686 (23.2)

58,210 (23.2)

0.2

30 – 39

17,183 (27.1)

67,628 (27.0)

0.2

40 – 49

15,382 (24.3)

60,766 (24.25)

0.0

50 – 59

10,069 (15.9)

39,925 (15.94)

0.2

Female

28,394 (44.8)

112,030 (44.7)

0.1

Male

35,016 (55.2)

138,509 (55.3)

0.1

1 (lowest)

19,818 (31.3)

49,954 (19.9)

26.1

2

14,065 (22.2)

49,889 (19.9)

5.6

3

11,133 (17.6)

49,918 (19.9)

6.1

4

9,793 (15.4)

50,033 (20.0)

11.9

5 (highest)

8,601 (13.6)

50,745 (20.3)

17.9

Yes

56,326 (88.8)

209,218 (83.5)

17.3

No

7,084 (11.2)

41,321 (16.5)

14.7

Urban

57,186 (90.2)

218,776 (87.3)

9.1

Rural

6,224 (9.8)

31,763 (12.7)

9.1

Psychiatric

Schizophrenia

38,004 (59.9)

--

--

Diagnosis

spectrum

25,406 (40.1)

--

--

(standard
deviation)

Sex

Neighbourhoodlevel Income
Quintile

Access to a
family
physician

Rurality of
residence

disorder
Psychosis
NOS
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Table 3.2: Incidence cancer cases by site and results of adjusted and unadjusted Poisson regression models of all-site and site-specific cancer incidence
among people with psychotic disorders

Events

Exposed

Unexposed

(n = 63,410)

(n = 250,539 )

IR (95% CI)

Events

(per 1000 person-years)
All Cancer

Incidence Rate Ratios (IRR)

IR (95% CI)

IRR (95% CI)

IRR (95% CI)

(per 1000 person-years)

(unadjusted)

(adjusted)*

5,069

4.47 (4.35, 4.59)

20,175

4.22 (4.17, 4.28)

1.06 (1.03, 1.09)

1.09 (1.05, 1.12)

Bladder

151

0.13 (0.11, 0.16)

639

0.13 (0.12, 0.14)

1.00 (0.83, 1.19)

1.04 (0.87, 1.25)

Brain

82

0.07 (0.06, 0.09)

356

0.07 (0.07, 0.08)

0.97 (0.76, 1.23)

0.99 (0.78, 1.26)

Breast (female only)

888

1.71 (1.60, 1.83)

3498

1.63 (1.58, 1.68)

1.05 (0.98, 1.13)

1.09 (1.01, 1.17)

Cervix (female only)

76

0.15 (0.12, 0.19)

212

0.10 (0.09, 0.11

1.49 (1.14, 1.93)

1.43 (1.10, 1.87)

Colorectal

484

0.43 (0.39, 0.47)

1,968

0.41 (0.39, 0.43)

1.04 (0.94, 1.14)

1.11 (1.00, 1.23)

Esophagus

66

0.06 (0.05, 0.07)

171

0.04 (0.03, 0.04)

1.63 (1.22, 2.16)

1.72 (1.29, 2.29)

Hodgkin’s Lymphoma

33

0.03 (0.02, 0.04)

104

0.02 (0.018, 0.03)

1.34 (0.90, 1.98)

1.33 (0.89, 1.97)

Kidney

165

0.15 (0.12, 0.17)

614

0.13 (0.12, 0.14)

1.13 (0.95, 1.34)

1.12 (0.94, 1.34)

Larynx

24

0.02 (.01, 0.03)

112

0.02 (0.02, 0.03)

0.90 (0.58, 1.40)

0.93 (0.59, 1.45)

Leukemia

298

0.26 (0.23, 0.29)

1,065

0.22 (0.21, 0.24)

1.18 (1.04, 1.34)

1.23 (1.08, 1.40)

Liver

83

0.07 (0.06, 0.09)

188

0.04 (0.03, 0.05)

1.86 (1.44, 2.41)

1.70 (1.31, 2.21)

Lung

793

0.70 (0.65, 0.75)

2,173

0.45 (0.44, 0.47)

1.54 (1.42, 1.67)

1.52 (1.40, 1.65)

Melanoma

134

0.12 (0.10, 0.14)

942

0.20 (0.18, 0.21)

0.60 (0.50, 0.72)

0.66 (0.55, 0.79)

Myeloma

<6

0.00 (0.00, 0.01)

17

0.00 (0.00, 0.01)

0.74 (0.22, 2.54)

0.81 (0.23, 2.81)

Non-Hodgkin’s Lymphoma

209

0.18 (0.16, 0.21)

800

0.17 (0.16, 0.18)

1.10 (0.94, 1.28)

1.11 (0.95, 1.30)
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Oral cavity

147

0.13 (0.11, 0.15)

562

0.12 (0.11, 0.13)

1.10 (0.92, 1.32)

1.12 (0.94, 1.35)

Ovary (female only)

83

0.07 (0.06, 0.09)

391

0.18 (0.17, 0.20)

0.88 (0.70, 1.12)

0.90 (0.71, 1.14)

Pancreas

85

0.07 (0.06, 0.09)

402

0.08 (0.08, 0.09)

0.89 (0.70, 1.13)

0.90 (0.71, 1.14)

Prostate (male only)

321

0.28 (0.25, 0.32)

2,519

0.95 (0.91, 0.99)

0.54 (0.48, 0.61)

0.59 (0.53, 0.66)

Stomach

77

0.07 (0.05, 0.08)

317

0.07 (0.06, 0.07)

1.02 (0.80, 1.31)

1.03 (0.80, 1.33)

Testis (male only)

56

0.09 (0.07, 0.12)

189

0.07 (0.06, 0.08)

1.26 (0.94, 1.70)

1.27 (0.94, 1.72)

Thyroid

192

0.17 (0.15, 0.19)

930

0.19 (0.18, 0.21)

0.87 (0.74, 1.02)

0.84 (0.72, 0.98)

Uterus (female only)

227

0.44 (0.39, 0.50)

800

0.38 (0.35, 0.40)

1.18 (1.02, 1.36)

1.19 (1.02, 1.38)

Other

392

0.85 (0.79, 0.90)

1,206

0.99 (0.96, 1.02)

0.85 (0.80, 0.92)

0.90 (0.84, 0.96)

Person-time at risk

425,400,000

1,814,000,000

* adjusted
for age, sex, income, rurality of residence, and access to a family physician
(1000
person-years)
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Table 3.3: Stage at diagnosis for people diagnosed with cancer in the exposed and unexposed groups
Exposed

Unexposed

n (%)

n (%)

(n = 5,069)

(n = 20,175)

I (early)

688 (13.6)

3,285 (16.3)

II

531 (10.5)

2,733 (13.6)

III

424 (8.4)

1,823 (9.0)

IV (metastatic)

565 (11.2)

1,974 (9.8)

2,861 (56.4)

10,360 (51.4)

Stage

Unknown

Table 3.4: Results of adjusted and unadjusted proportional odds models of stage at diagnosis excluding
people with missing stage data, and logistic regression model of the odds of missing stage at diagnosis among
people with psychotic disorders are reported
Stage at diagnosis

OR (95% CI)

Diagnosis with NAPD
1.23 (1.13, 1.34)
(unadjusted)
Diagnosis with NAPD
1.16 (1.06, 1.27)
(adjusted)*
Diagnosis with NAPD
1.24 (1.17, 1.32)
(unadjusted)
Diagnosis with NAPD
1.23 (1.15, 1.32)
(Adjusted)*
* adjusting for age, sex, income, rurality of residence, access to a family physician, and primary cancer site
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Chapter 4
4 Integrated Discussion
This chapter will discuss the findings of the two manuscripts of this thesis together in the
context of literature on cancer incidence and stage at diagnosis in people with psychotic
disorders. Importantly, we will consider the methodological limitations of this thesis and the
potential impact on our findings. Lastly, we will describe how our findings should shape future
investigations into this topic and specifically, which questions remain to be answered.

4.1 Key Findings
The objective of this thesis was to use systematic review methodology, as well as Ontario
health administrative data, to study the incidence of cancer and stage at diagnosis among people
with psychotic disorders, relative to the general population. Our systematic review and metaanalysis presented in chapter 2 synthesized the existing literature on cancer incidence and stage
at diagnosis in people with psychotic disorders – including both affective and non-affective – to
the general population, identifying methodological strengths and shortcomings of the current
literature. The findings from this review helped to inform the retrospective cohort study in
chapter 3, which compared cancer incidence and stage at diagnosis in people with non-affective
psychotic disorder to a comparison group sampled from the general population, using
population-based health administrative data from Ontario.
The systematic review found that the incidence of all-site cancer among people with
psychotic disorder was slightly elevated (RR: 1.08, 95% CI: 1.00, 1.16), although the 95% CI
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includes the possibility of a null effect. Differences in incidence were identified by cancer site.
People with psychotic disorder were found to have a higher risk of developing brain, breast,
nasopharyngeal, cervical, and uterine cancers; while having a lower risk of colorectal, prostate,
and skin cancer. Additionally, we found that people with psychotic disorder had a higher odds of
metastases at diagnosis, compared to people without psychotic disorders. Common sources of
bias identified across the included studies were the inability to ensure the outcome of interest
was absent at the start of the study, failure to include important confounding factors, and variable
reporting regarding the case definition used to identify people with psychotic disorders.
The cohort study found that the incidence of all-site cancer was elevated among people
diagnosed with non-affective psychotic disorder, relative to those without psychotic disorder
(IRR: 1.09, 95% CI: 1.05, 1.12), adjusting for age, sex, income, rurality of residence, and access
to a family physician. Similar to the systematic review, we found that people with psychotic
disorders had a higher incidence of breast, cervical, and uterine cancer, and a lower incidence of
prostate and skin cancer. We additionally identified an elevated incidence of lung cancer,
esophageal cancer, and leukemia, and a lower incidence of thyroid cancer, which was not found
in the systematic review. We also found evidence of significant effect modification by sex.
Specifically, females with psychotic disorder were found to have a higher incidence of cancer
overall, compared to females without psychotic disorder, but no difference was found for males.
However, after excluding prostate cancer in males, the effect of psychotic disorder on overall
cancer incidence was the same for both sexes.
Our cohort study also identified a greater odds of more advanced stage cancer at
diagnosis, consistent with the results of our meta-analysis. These findings could indicate the
presence of a diagnostic delay for people with psychotic disorder. Additionally, our post-hoc
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analysis of missing stage at diagnosis found that people with psychosis had a higher odds of
having a missing stage at diagnosis.

4.2 Results in Context
The results of this thesis suggest that the higher incidence of cancer in people with PD is
largely driven by higher rates of common cancers, including breast, colorectal, cervical, and lung
cancer. The higher incidence of cancer at these specific sites highlights a number of inequities in
health outcomes faced by those with psychotic disorder, driven by exposure to risk factors, as
well as differences in screening behavior and access of treatment, and increased risk of other
comorbidities. Therefore, the presence of any genetic factor which may be associated with lower
cancer risk in people with psychotic disorders, is likely overcome by these other risk factors,
should it exist at all. Furthermore, this hypothesized genetic factor may provide very little utility
in our understanding of this relationship until all other environmental, lifestyle, and behavioral
factors influencing cancer incidence can be accounted for and adequately addressed.
In chapter 3, we explored how a number of risk factors for cancer could have influenced
our results. Firstly, people with psychotic disorder are more likely to smoke, and smoke at higher
rates compared to the general population,65,240–244 thereby contributing to higher incidence of
lung, head/neck, and esophageal cancers,1,2,127,201 among others. Secondly, treatment with
antipsychotic medication has been shown to exhibit highly variable effects on the risk of specific
cancers.144,146–148,157 Hyperprolactinemia resulting from treatment with this class of medications
has been hypothesized to increase the risk of developing breast and uterine cancer and decrease
the risk of prostate cancer, due to the hormone-sensitivity of these cancers.146–148 We found that a
lower incidence of prostate cancer in males with psychotic disorder was responsible for the effect
measure modification by sex that we observed. Thirdly, people with psychotic disorder are more
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likely to have poor eating habits and a sedentary lifestyle, which contribute to increased risk of
cardiometabolic disorders, such as diabetes mellitus and obesity, which are identified risk factors
for breast and colorectal cancer, while diabetes may provide a protective effect against the
development of prostate cancer.5,24,44–48,161,162 This risk is worsened by exposure to antipsychotic
medications through the overstimulation of appetite and increased risk of insulin resistance. 56,58,59
Furthermore, exposure to factors such as smoking, obesity, and insulin resistance among people
with psychotic disorders are driven, in part, by stressful living environments and limited access
to financial resources,245,246 as people with psychotic disorders are likely to be of lower SES
compared to the general population.247 Finally, people with psychotic disorders have higher
odds of having hepatitis infections compared to the general population, driven by injection drug
use, risky sexual behaviour, and low vaccination rates, which is known to account for a majority
of hepatocellular carcinoma worldwide.228–231
Differences in screening behaviour and uptake may also be responsible for our findings.
People with psychotic disorder are far less likely to participate in screening for breast, cervical,
prostate, and colorectal cancer, compared to the general population, resulting in later stage at
diagnosis.164,167,179–181 Widespread screening for cervical and colorectal cancer, along with the
ability to remove pre-cancerous lesions, has translated into dramatic reductions in the incidence
of these cancers over time.77,80–82,232 Because people with psychotic disorder are less likely to
participate in these programs, it is possible that we would not see the same reductions in
incidence over time as we have seen in the general population. Conversely, prostate and breast
cancer have been over-diagnosed in the general population as the result of excessive
screening.83–85,232,233 Therefore, low adherence to these screening programs may result in under
detection of breast and prostate cancer, relative to the general population. Additionally, this lack
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of screening uptake for other cancers could apply to melanoma, potentially explaining the lower
incidence observed in people with NAPD.150,235
Although later stage at diagnosis does contribute to higher mortality rates among people
with psychotic disorder, this does not account for the entirety of the excess mortality.168
Physicians’ perceptions of patients with psychotic disorder have further health consequences in
this population, through diagnostic and treatment overshadowing.236 Diagnostic overshadowing
refer to the phenomena whereby physicians misattribute symptoms of physical illnesses to a
person’s pre-existing mental illness diagnoses, such that the physical illnesses may be
overlooked.236 Although difficult to quantify, the effects of diagnostic overshadowing can be
seen in the disparities in receipt of treatment by people with mental illnesses. 236 An example can
be found in treatment for ischemic heart disease, where people with psychotic disorder were less
likely to receive revascularization procedures compared to people without psychotic
disorder.248,249 A cohort study using Ontario health administrative data found that people with
serious mental illnesses (SMI), including schizophrenia, schizoaffective disorder, major
depression, and other bipolar disorder, were significantly less likely to receive surgical resection
or adjuvant treatment for colorectal cancer, compared to those without SMI, translating to a
higher mortality risk.202 Furthermore, people with psychotic disorders are less likely to receive
adequate medical management of physical illnesses, as physicians may doubt a patient’s ability
to adhere to treatment and lifestyle interventions, in a phenomenon termed ‘nihilistic
overshadowing’.245
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4.3 Strengths and Limitations
This thesis must be considered within the larger body of literature examining cancer
incidence and stage at diagnosis among people with psychotic disorders. Our meta-analysis
provided a comparison of cancer risk among people with psychosis by synthesizing data from a
broader array of studies than has been done previously. Our retrospective cohort study is the first
to examine cancer incidence and stage at diagnosis among people with psychotic disorders in
Ontario. The use of population-based health administrative data in a country with universal
healthcare allows for a substantial follow-up period of a large, representative sample.
Furthermore, our retrospective cohort study represents one of very few studies which examine
incidence and stage at diagnosis within the same cohort.
The systematic review in chapter 2 should be considered in light of its limitations. Firstly,
there was a high degree of statistical heterogeneity present in our meta-analyses. This was likely
because our meta-analyses included a variety of effect estimates with varying levels of
adjustment for confounding factors. These estimates were included in order to analyze a wider
range of studies with varying methodology; however, this may have introduced a substantial
degree of statistical heterogeneity. Secondly, our literature search did not include unpublished
literature or grey literature. Therefore, introducing potential publication bias as well as excluding
a body of potentially relevant literature. Furthermore, our Egger’s test was underpowered to
detect publication bias for studies examining stage at diagnosis. As such, it is unclear whether
publication bias was present in our meta-analysis of stage at diagnosis.
This thesis was limited by the availability of data within the health administrative
databases. The OCR does not contain cases of basal or squamous cell carcinomas of the skin,
thereby minorly limiting our ability to examine a number of cancer types.238 Additionally, the
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incidence of myeloma, laryngeal cancer, and Hodgkin’s lymphoma were low within our cohort.
Therefore, the validity of estimates and conclusions drawn about these particular cancers is
limited. Moreover, there was a large proportion of missing data for stage at diagnosis among
people diagnosed with cancer over the follow-up period, with people in the exposed group being
more likely to have missing stage data. If people with missing stage data differ systematically
from those with complete stage data, this may limit the generalizability of our analyses of stage
at diagnosis. Furthermore, there are low rates of screening for colorectal, breast, prostate, and
cervical cancer among people with psychotic disorders,164,167,179–181 which may introduce
detection bias for these cancers.
There was a potential for misclassification among our exposed group as a result of a high
sensitivity of our case definition used to identify people with psychotic disorders. However, we
expect that this misclassification was nondifferential by outcome status. Additionally, our case
definition was limited to people diagnosed with nonaffective psychotic disorder, therefore our
conclusions may not be generalizable to people with affective psychoses.
Because our cohort was restricted to people aged 15 to 59 at the index date, the conclusions
drawn from our cohort study may only apply to those within this age range. Additionally, our
conclusions may be limited to cancers which commonly occur in younger people.239
Finally, because health administrative data is designed for billing rather than research
purposes, we were not able to adjust for a number of important confounding factors such as
antipsychotic medication exposure, obesity, smoking, and a number of other lifestyle factors
which contribute to cancer risk.1,5,24,44–48,144 As we explored in the discussion of chapters 2 and 3,
factors associated with obesity and cardiometabolic disorders likely have a substantial influence
on the risk of a number of cancers, including breast, colorectal, and prostate cancer.104,105,161
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Therefore, we are not able to understand the pathway from psychotic disorder diagnosis to
cancer incidence without adjustment for these factors.

4.4 Future Directions
Future research regarding this topic should be more transparent in the reporting of case
definitions used to identify people with psychotic disorders and the extent to which missing data
may have had an influence on the results. Additional studies should be conducted using
population-based health administrative data in countries with universal healthcare in order to
improve the representativeness of samples to the general population and improve comparability
of study populations.
Future research should work to quantify the effects of antipsychotic medication exposure
and comorbidities such as obesity and diabetes, which occur in higher rates among people with
psychotic disorders,5,24,44–48 and are demonstrated risk factors for a number of cancers.104,105 In
addition to the varying effects of antipsychotic medication on cancer risk by site,144,146–148,157
treatment with anti-psychotic medication has been found to worsen the risk of cardiometabolic
disorders.28,29 The intermediary effects of these variables in the relationship between psychotic
disorder diagnosis and cancer, should be examined along with screening uptake and vaccination
coverage.
In the future, we will use the cohort identified in chapter 3 in order to examine how
treatment decisions, following a cancer diagnosis, influence cancer-specific and all-cause
mortality among people with PD. Mahar et al. have suggested that disparities in reception of
treatment by patients with colorectal cancer, may account for a portion of the 69% higher
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mortality risk among people with severe psychiatric illnesses, as patients with severe mental
illnesses were less likely to receive surgical resection or adjuvant treatment. 202
Furthermore, efforts should be made to educate and improve awareness regarding cancer
screening programs and increase uptake of vaccinations for HPV and hepatitis among this
vulnerable population.

4.5 Conclusion
This thesis identified a significantly elevated cancer incidence among people with
nonaffective psychotic disorders, relative to people without psychotic disorders. The magnitude
and direction of this effect varied significantly by cancer site. Additionally, we observed effect
modification by sex, which was likely driven by the lower incidence of prostate cancer among
people with NAPD. These differences in cancer incidence are likely the product of
environmental, lifestyle, and socioeconomic risk factors among people with psychotic disorders,
along with poor screening behaviour.
The evidence of more advanced stage cancer at diagnosis is reflective of a diagnostic delay
and differential access to care for people with psychosis. These differences are likely driven, in
part, by misperceptions, stigma, and diagnostic overshadowing on the part of healthcare
providers, as well as health-seeking behaviours of people with psychotic disorders.237 It is
important to note that these differences are observed in a country with universal healthcare,
wherein cost barriers in access to care are minimal.
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Appendix 2A: PRISMA Checklist
Section and
Topic

Item
#

Checklist item

Location
where item
is reported

TITLE
Title

1

Identify the report as a systematic review.

15

ABSTRACT
Abstract

2

See the PRISMA 2020 for Abstracts checklist.

15

INTRODUCTION
Rationale

3

Describe the rationale for the review in the context of existing knowledge.

16 – 17

Objectives

4

Provide an explicit statement of the objective(s) or question(s) the review addresses.

18

METHODS
Eligibility criteria

5

Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.

18 – 19

Information
sources

6

Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the
date when each source was last searched or consulted.

18

Search strategy

7

Present the full search strategies for all databases, registers and websites, including any filters and limits used.
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Selection process

8

Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record
and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.

18 – 19

Data collection
process

9

Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked
independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the
process.

19

10a

List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each
study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.

19

10b

List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any
assumptions made about any missing or unclear information.

19

Data items

Study risk of bias
assessment

11

Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each
study and whether they worked independently, and if applicable, details of automation tools used in the process.

19

Effect measures

12

Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.

19 – 20
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Section and
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Synthesis
methods

Item
#

Checklist item
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where item
is reported
20

13a

Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and
comparing against the planned groups for each synthesis (item #5)).

13b

Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data
conversions.

20 – 21

13c

Describe any methods used to tabulate or visually display results of individual studies and syntheses.

20 – 21

13d

Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the
model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.

21

13e

Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).

21

13f

Describe any sensitivity analyses conducted to assess robustness of the synthesized results.

20 – 21

Reporting bias
assessment

14

Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).

21

Certainty
assessment

15

Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.

20 – 21

16a

Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in
the review, ideally using a flow diagram.

21 – 22

16b

RESULTS
Study selection

Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.

22

Study
characteristics

17

Cite each included study and present its characteristics.

Table 2.1

Risk of bias in
studies

18

Present assessments of risk of bias for each included study.

Figure 2.3

Results of
individual studies

19

For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision
(e.g. confidence/credible interval), ideally using structured tables or plots.

Appendices
2H and 2I

20a

For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.

Appendix
2C

20b

Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g.
confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.

Figures 2.4
– 2.6

20c

Present results of all investigations of possible causes of heterogeneity among study results.

Figures 2.4
– 2.6

20d

Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.

23 – 25

Results of
syntheses

Reporting biases

21

Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.

23 – 25

Certainty of
evidence

22

Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.

23 – 25
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Checklist item

Location
where item
is reported

23a

Provide a general interpretation of the results in the context of other evidence.

25 – 29

23b

Discuss any limitations of the evidence included in the review.

29 – 30

23c

Discuss any limitations of the review processes used.

30 – 31

23d

Discuss implications of the results for practice, policy, and future research.

31 – 32

Provide registration information for the review, including register name and registration number, or state that the review was not registered.

4

Indicate where the review protocol can be accessed, or state that a protocol was not prepared.

4

Describe and explain any amendments to information provided at registration or in the protocol.

NA

Section and
Topic

Item
#

DISCUSSION
Discussion

OTHER INFORMATION
Registration and
24a
protocol
24b
24c
Support

25

Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.

32

Competing
interests

26

Declare any competing interests of review authors.

32

Availability of
data, code and
other materials

27

Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included
studies; data used for all analyses; analytic code; any other materials used in the review.

32
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Appendix 2B: Search strategy
Medline (via
Ovid)
exp
neoplasms/ or
cancer.mp.

PsychNFO
(via Ovid
exp
neoplasms/ or
cancer.mp.

Database
EMBASE
(Via Ovid)
Cancer.mp. or
exp malignant
neoplasm/

Psychotic
disorders

exp
"schizophrenia
spectrum and
other
psychotic
disorders"/ or
(Psychosis or
psychotic or
schizophreni*
or sever*
mental ill* or
sever* mental
disorder*).mp.

exp psychosis/
or (Psychosis
or psychotic or
schizophreni*
or sever*
mental ill* or
sever* mental
disorder*).mp.

exp psychosis/
or (Psychosis
or psychotic or
schizophreni*
or sever*
mental ill* or
sever* mental
disorder*).mp.

(MH
"Psychotic
Disorders+")
OR
"psychosis"
OR
"psychotic"
OR
schizophreni*
OR "sever*
mental ill*"
OR "sever*
mental
disorder"

Psychotic
disorders or
schizophrenia or
severe mental
illnesses

Incidence and
staging

cancer
staging.mp. or
exp Neoplasm
Staging/ or
incidence.mp.
or exp
Incidence/

exp morbidity/
or
morbidity.mp.
or
incidence.mp.
or (cancer
staging or
staging).mp.

exp cancer
staging/ or exp
staging/ or
staging.mp. or
cancer
staging.mp.
or cancer
incidence.mp.
or exp cancer
incidence/

(MH
"Neoplasm
Staging") OR
"cancer
staging" OR
"staging" OR
(MH
"Incidence")
OR inciden*

Cancer incidence
or cancer staging

Results

231

139

374

323

Concept
cancer

117

CINAHL

Keywords

(MH
Cancer or
"Neoplasms+") neoplasms
OR cancer

Appendix 2C: Results of Risk of Bias Assessment
Citation

1. Is the source
population
representative of
the general
population?

Chen et al., 2018

low risk

Dalton et al., 2005

low risk

Chou et al., 2011

2. Was selection of
exposed and nonexposed cohorts
drawn from the
same population?

intermediate
risk
low risk

intermediate
risk
low risk

low risk

intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
low risk

low risk

high risk

Kisley et al., 2013

intermediate
risk
low risk

intermediate
risk
intermediate
risk
low risk

Dalton et al., 2008

low risk

low risk

Truers et al., 2011

low risk

low risk

Chou et al., 2017

low risk

low risk

Barak et al., 2005

intermediate
risk
low risk

intermediate
risk
low risk

low risk

low risk

intermediate
risk
low risk

low risk

low risk

low risk

high risk

low risk

intermediate
risk
low risk

intermediate
risk
low risk

high risk

low risk
low risk

Raviv et al., 2014

intermediate
risk
intermediate
risk
high risk

Levav et al., 2007

high risk

Ji et al., 2012

low risk

intermediate
risk
low risk

Manderbacka et al., 2017

low risk

low risk

Dalton et al., 2008

low risk

low risk

Cunningham et al., 2015

low risk

low risk

Scheflen, 1951

high risk

Toender et al., 2018

low risk

intermediate
risk
low risk

Lawrence et al., 2000

low risk

low risk

Pettersson et al., 2020
Hippisley-Cox et al., 2007

low risk
low risk

low risk
low risk

Lin et al., 2013
Goldacre et al., 2005
Grinshpoon et al., 2005
Levav et al., 2009
Liao et al.2015
Kisley et al., 2016
Lin et al., 2013
McGinty et al., 2012
Mortensen et al., 1989

Mortensen, 1994
Lichtermann et al., 2001
Ishikawa et al., 2016
Ahlgrén-Rimpiläinen et al.,
2020
Arffman et al., 2019
Baillargeon et al., 2011
Barak et al., 2008
Brink et al., 2019
Bergamo et al., 2014
Chang et al., 2013
Osborn et al., 2013

low risk

low risk
low risk
low risk
low risk
low risk

low risk

low risk
low risk

3. Can we be
confident in the
assessment of
exposure?

4. Can we be
confident in the
assessment of
outcome?

5. Can we be
confident that the
outcome of
interest was not
present at start of
study?

6. Did the study match
exposed and unexposed
for all variables that are
associated with the
outcome of interest or
did the statistical
analysis adjust for these
prognostic variables?

7. Can we be
confident in the
assessment of the
confounding
factors?

intermediate
risk
intermediate
risk
low risk

low risk

low risk

intermediate risk

low risk

low risk

intermediate risk

low risk

low risk

intermediate
risk
high risk

intermediate risk

low risk

intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
not reported

low risk

low risk

intermediate risk

low risk

low risk

intermediate risk

low risk

intermediate
risk
low risk

low risk

8. Was the follow
up of cohorts
adequate?

9. Is there little
missing data?

intermediate
risk
low risk

not reported

intermediate
risk
low risk

low risk

intermediate
risk
intermediate
risk
low risk

intermediate risk

low risk

low risk

not reported

low risk

intermediate risk

low risk

low risk

not reported

low risk

low risk

intermediate risk

low risk

not reported

low risk

high risk

high risk

low risk

intermediate
risk
high risk

low risk

intermediate risk

low risk

intermediate risk

low risk

not reported

low risk

high risk

intermediate risk

low risk

intermediate
risk
intermediate
risk
low risk

not reported

low risk

intermediate
risk
high risk

low risk

low risk

intermediate risk

low risk

low risk

low risk

intermediate
risk
low risk

low risk

intermediate
risk
low risk

low risk

low risk

low risk

intermediate risk

low risk

intermediate
risk
low risk

low risk

intermediate
risk
low risk

low risk

low risk

intermediate
risk
intermediate
risk
low risk

intermediate risk

low risk

intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
not reported

low risk

intermediate
risk
low risk

intermediate risk

low risk

intermediate risk

low risk

low risk

intermediate
risk
low risk

low risk

low risk

low risk

low risk

low risk

low risk

low risk

low risk

intermediate
risk
intermediate
risk
low risk

intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
not reported

low risk

intermediate
risk
intermediate
risk
intermediate
risk
low risk
not reported

low risk

low risk

low risk

low risk
low risk
low risk

not reported

not reported

not reported

not reported
low risk

not reported
low risk

intermediate
risk
intermediate
risk
low risk

intermediate
risk
not reported

low risk

low risk

intermediate
risk
low risk

low risk

low risk

low risk

not reported

low risk

low risk

low risk

intermediate risk

low risk

intermediate
risk
low risk

not reported

intermediate risk

low risk

low risk

low risk

low risk

low risk

low risk

not reported

intermediate risk

low risk

low risk

intermediate risk

low risk

intermediate
risk
low risk

intermediate risk

low risk

not reported

intermediate risk

low risk

intermediate
risk
low risk

intermediate risk

low risk

low risk

low risk

not reported

low risk

low risk

intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
intermediate
risk
low risk

low risk

low risk

intermediate risk

low risk

low risk

not reported

low risk

low risk

low risk

low risk

low risk

low risk

low risk

low risk

low risk

intermediate
risk
low risk

intermediate
risk
low risk

high risk
low risk

intermediate
risk
low risk

intermediate
risk
intermediate
risk
not reported

low risk

low risk

intermediate risk

low risk

low risk

intermediate
risk
low risk

low risk
low risk

low risk
low risk

intermediate risk
low risk

low risk
intermediate
risk

low risk
low risk

low risk
low risk

low risk
low risk
low risk
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low risk

low risk

not reported

low risk
not reported

Appendix 2D: Meta-analysis of overall cancer incidence sub-grouped by country
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Appendix 2E: Meta-analysis of overall cancer incidence sub-grouped by specific psychotic disorder
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Appendix 2F: Funnel Plot of cancer incidence
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Appendix 2G: Funnel Plot of odds of metastases at diagnosis
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Appendix 2H: Summary of findings table for studies which reported on cancer incidence
Exposed
Citation

Psychotic Disorder

subsample

Cancers

Outcome

No
Outcome

Unexposed

Crude

Total

Person
Time
(P-Y)
(IR)

Outcome

No
Outcome

Total

Person
Time (IR)

Crude
incidence
measure

Point
Estimate

Adjusted
lower
(95%)

upper
(95%)

Adjusted
Measure

Point
Estimate

lower
(95%)

upper
(95%)

Covariates

Barak et al., 2005

schizophrenia

all cancer

120

3106

3226

NR

NR

NR

NR

NR

SIR

0.58

0.48

0.69

age

Barak et al., 2008

schizophrenia

all cancer

139

1872

2011

NR

NR

NR

NR

NR

SIR

0.56

0.47

0.66

age

Breen, 1981

schizophrenia

all cancer

24

38

62

NR

25

37

62

NR

Brink et al., 2019

schizophrenia

all cancer

632

3912

4544

107833

3605

18992

22597

623822

Chen et al., 2018

schizophrenia

all cancer

514

32217

32731

238509

schizophrenia

Lung, stomach,
liver, colorectal,
esophagus,
prostate,
breast,
cervical/uterine,
other

Chou et al., 2011

1145

58112

59257

NR

Chou et al., 2017

schizophrenia

breast

119

10608

10727

87114

Dalton et al.,
2005

schizophrenia

all cancer

1394

21372

22766

292230

Dalton et al.,
2008

schizophrenia and
other psychoses

males

lung

females

Dalton et al.,
2008

schizophrenia and
other psychoses

males

all cancer

females

Goldacre et al.,
2005

Grinshpoon et
al., 2005

10662

178156

10727

NR

88811

Cox (HR)

HR

0.64

1.88

0.6

1.39

0.69

2.54

HR

1.15

0.71

1.06

0.66

1.26

age

0.75

gender, urbanization,
Charlson Comorbidity
Index Score (CCIS),
monthly income, age

HR

1.94

1.43

2.63

age, occupation,
monthly income,
comorbidities,
medications

SIR

0.98

0.93

1.02

age

143

14841

14984

139396

11496

1486926

1498422

24915314

IRR

1.67

1.42

1.97

IRR

3.03

2.57

3.58

153

13787

13940

140218

8997

1457779

1466776

12414122

IRR

1.54

1.31

1.81

IRR

2.51

2.14

2.94

NR

NR

NR

NR

NR

NR

NR

NR

IRR

1.47

NR

NR

NR

NR

NR

NR

NR

NR

IRR

1.4

education, disposable
income, employment
status, social class,
housing tenure, size
of dwelling,
cohabiting status,
district type,
ethnicity, charston
comorbidity index,
depression
education, disposable
income, employment
status, social class,
housing tenure, size
of dwelling,
cohabiting status,
district type,
ethnicity, charston
comorbidity index,
depression
age, period,
education, disposable
income
age, period,
education, disposable
income

schizophrenia

all cancer

486

9163

9649

NR

26926

NR

~600000

NR

standardized
RR

0.99

0.9

1.08

age, gender, year

schizophrenia

lung, breast,
melanoma,
brain, corpus
uteri, prostate

602

NR

NR

336109

NR

NR

NR

NR

SIR

0.86

0.8

0.93

age

902

NR

NR

288755

NR

NR

NR

NR

SIR

0.91

0.85

0.97

age

males

females
Hippisley-Cox et
al., 2007

65

172862

schizophrenia

Significantly reduced risk of all cancers overall. Significantly
reduced risk of stomach and rectal cancer. Reduced risk of
prostate cancer
Women with schizophrenia had a reduced incidence of cancer
overall compared to the general population. Women with
schizophrenia had a reduced incidence of breast cancer
compared to the general population. Increased risk of cervical
uteri cancer among women with schizophrenia.
more patients in control group died of lung cancer compared to
the patients with schizophrenia.

SIR

5294

Other Findings

all cancer

Ji et al., 2012

schizophrenia

all cancer

5101

53096

58197

NR

NR

NR

NR

NR

SIR

1

0.97

1.03

age, gender, calendar
period, SES,
residential area,
comorbidity

Kisley et al., 2013

schizophrenia

all cancer

129

NR

NR

NR

NR

NR

NR

NR

standardized
RR

0.79

0.61

1.02

age

affective
psychoses

358

NR

NR

NR

NR

NR

NR

NR

standardized
RR

0.85

0.75

0.98

age

other psychoses

302

NR

NR

NR

NR

NR

NR

NR

standardized
RR

1.14

1.01

1.28

age

123

People with schizophrenia between the ages of 50-59 had an
increased risk of cancer, compared to the general population.
higher incidence of cancer overall in people with schizophrenia,
relative to the general population. Females with schizophrenia
had a higher incidence of breast and bladder cancer compared to
the general population. Males with schizophrenia had a higher
incidence of colorectal cancer.

people with schizophrenia had an increased risk of cancer,
compared to those without schizophrenia.

females with schizophrenia were 1.88 (95% CI: 1.39–2.54) times
more likely to develop breast cancer, even after adjusting for
confounding factors (aHR: 1.94, 95% CI: 1.43–2.63). Risk of
breast cancer significantly higher in females receiving
combination of FGAs and SGAs. Compared with the nonschizophrenia cohort, the aHRs of breast cancer were nearly 2fold regardless of the mean FGA exposure dosage
No difference in cancer incidence for people with schizophrenia,
relative to the general population. Elevated SIR during the first
year of follow-up. Decreased risk of rectal cancer, prostate
cancer, and non-melanoma skin cancers among males with
schizophrenia. Female patients with schizophrenia had an
increased risk of breast cancer.

incidence rates of lung cancer decreased with increasing social
advantage (education, income, closer affiliation to work market,
housing tenure, larger housing). Presence of somatic or
psychiatric disorders increased IRR.

In persons with schizophrenia, the incidence rates of lung,
breast, and cervix cancer were increased and the incidence rate
of prostate cancer was reduced.

No difference in cancer risk overall among people with
schizophrenia, compared to the reference group. Incidence of
esophageal cancer elevated in those with schizophrenia. Skin
cancer, rectal cancer, colon cancer lower in people with
schizophrenia.
incidence of cancer overall was lower for both males and
females with schizophrenia, compared to the general
population. Males with schizophrenia had an increased risk of
lung cancer. Females with schizophrenia had an increased risk of
cancers of corpus uteri and breast.
people with schizophrenia had significantly increased risk of
breast and colon cancer, but a lower risk of respiratory cancer.
Increased breast cancer risk not affected by antipsychotic
medication use.
people with schizophrenia had a decreased incidence of cancer
overall, compared to the general population. Decrease was more
pronounced before the first diagnosis of schizophrenia.
Increased risk of liver, breast, cervix, and endometrium cancer
and unknown primary after first diagnosis. adjusting for smoking
reduced incidence of urinary and bladder cancers, but increased
breast and endometrium cancer. When restricting to cancer
after first diagnosis, male patients with schizophrenia had lower
incidence than the general population, while female patients had
a higher risk. overall risk was significantly reduced among
unaffected parents and siblings. Breast cancer had increased risk
irrespective of follow-up time and period after first diagnosis--in
attempts to evaluate effects of antipsychotic treatment.
overall incidence of cancer lower in people with psychiatric
illnesses. Statistically significantly lower cancer incidence in
males with affective psychoses, stress or adjustment reactions,
and non-specific psychiatric diagnoses.

Exposed
Citation

Kisley et al., 2016

Lawrence et al.,
2000

Levav et al., 2007

Psychotic Disorder

subsample

Cancers

No
Outcome

Total

Person
Time (IR)

NR

NR

NR

NR

NR

NR

319

NR

NR

NR

NR

NR

185

NR

NR

NR

NR

223

NR

NR

NR

affective
psychoses
other psychoses

Point
Estimate

lower
(95%)

upper
(95%)

Adjusted
Measure

Point
Estimate

lower
(95%)

upper
(95%)

Covariates

Other Findings

NR

standardized
RR

0.95

0.81

1.08

age

cancer incidence lower in people with psychotic disorders
compared to the general population.

NR

NR

standardized
RR

1.15

1.02

1.28

age

NR

NR

NR

standardized
RR

1.24

1

1.48

age

NR

NR

NR

NR

SIR

0.83

0.7

0.98

age, gender

males

schizophrenia
affective
psychoses
affective
psychoses
other psychoses
other psychoses

females

273

NR

NR

NR

NR

NR

NR

NR

SIR

1.13

0.99

1.28

age, gender

males

211

NR

NR

NR

NR

NR

NR

NR

SIR

0.91

0.76

1.07

age, gender

females

401

NR

NR

NR

NR

NR

NR

NR

SIR

1.06

0.94

1.19

age, gender

males
females

118
149

NR
NR

NR
NR

NR
NR

NR
NR

NR
NR

NR
NR

NR
NR

SIR
SIR

1.22
0.95

1.02
0.78

1.47
1.17

age, gender
age, gender

schizophrenia

males

all cancer

Crude
incidence
measure

Adjusted

schizophrenia

all cancer

schizoaffective
disorder

males

all cancer

females

Liao et al., 2015

Outcome

236

females

Levav et al., 2009

Total

Outcome

all cancer

Crude

Person
Time
(P-Y)
(IR)

No
Outcome

schizophrenia

Unexposed

hepatocellular
carcinoma

schizophrenia

28

4045

4073

NR

NR

NR

NR

NR

SIR

0.88

0.55

1.78

age, gender, country
of origin

14

2045

2059

NR

NR

NR

NR

NR

SIR

0.78

0.37

1.19

age, gender, country
of origin

12

1191

1203

13445

NR

NR

NR

NR

SIR

1.11

0.48

1.73

age

42

1155

1197

13445

NR

NR

NR

NR

SIR

1.38

0.96

1.8

age
age, diabetes
mellitus, cirrhosis,
alcoholic liver
damage, other
chronic hepatitis,
hepatitis B

16

2521

2537

16351

35

9393

9428

68452

IRR

1.91

1.67

2.19

HR

1.93

1.07

3.49

Lichtermann et
al., 2001

schizophrenia

all cancer

724

26272

26996

446653

NR

NR

NR

NR

SIR

1.17

1.09

1.25

age, calendar period

Lin et al., 2013

schizophrenia

all cancer

1738

100464

102202

774691

NR

NR

NR

NR

SIR

0.92

0.9

0.96

age, sex, follow-up
time

Lin et al., 2013

schizophrenia

all cancer

1129

70188

71317

NR

NR

NR

NR

NR

SIR

1.17

1.08

1.28

age, sex, follow-up
time

367

20200

20567

NR

NR

NR

NR

NR

SIR

1.29

1.11

1.51

age, sex, follow-up
time

bipolar disorder

McGinty et al.,
2012

all except nonmelanoma skin
cancer

schizophrenia

bipolar disorder

155

2160

2315

19855

NR

NR

NR

NR

SIR

2.6

2.2

3

age

75

927

1002

8405

NR

NR

NR

NR

SIR

2.6

2

3.2

age

Mortensen et al.,
1989

schizophrenia

all cancer

1028

5124

6152

NR

NR

NR

NR

NR

SIR

0.9

age

Mortensen, 1994

schizophrenia

all cancer

133

9023

9156

NR

NR

NR

NR

NR

SIR

0.79

age, gender, calendar
period

Osborn et al.,
2013

schizophrenia and
other psychoses

all cancer

380

20252

20632

NR

2356

113796

116152

NR

IRR

0.98

0.88

1.09

age, sex, period,
deprivation

Pettersson et al.,
2020

schizophrenia

all cancer

11670

99636

111306

424829

NR

NR

NR

NR

IRR

1.02

0.91

1.13

age, sex, calendar
period

Raviv et al., 2014

schizophrenia

all cancer

181

4145

4326

NR

NR

NR

NR

NR

SIR

0.52

0.45

0.61

age

all cancer

NR

NR

NR

NR

NR

NR

NR

NR

all cancer

NR

NR

NR

NR

NR

NR

NR

NR

Scheflen, 1951

Toender et al.,
2018

schizophrenia,
bipolar, affective
psychosis, nonorganic psychosis
schizophrenia,
bipolar disorder,
schizoaffective
disorder

males

IRR

0.95

0.85

1.06

lower cancer incidence rates were observed in males with
schizophrenia and dementia and both male and female patients
with non-specific psychiatric diagnoses.

Both parents, including those with schizophrenia had a reduced
cancer risk compared to the general population. When excluding
parents with schizophrenia, this remained unchanged. Lower
ratios were found for gender-concordant pairs of offspring and
parents.

People with schizoaffective disorder did not have significantly
different incident rates for cancer than the general population or
people with bipolar disorder. Cancer incidence among female
patients with schizoaffective disorder significantly higher than
among female patients with schizophrenia.
higher incidence of hepatocellular carcinoma in those with
schizophrenia than those without schizophrenia. Schizophrenia
group aged 40-64 had the highest incidence of HCC, but the
schizophrenia group aged 20-39 had the highest risk of HCC (IRR:
4.03, 95% CI: 3.42 to 4.75).
increased overall incidence of cancer in people with
schizophrenia. Increased for cancers of lung, pharynx,
gallbladder. Decreased incidence of rectal cancer. Decreased
incidence of cancer for relatives, compared to the general
population. Cancer incidence in siblings and parents of those
with schizophrenia was lower than the general population.
patients with schizophrenia had a significantly lower risk of
cancer overall, compared to the general population. Elevated
risk of cancers in nasopharynx, brain, breast, uterine cervix
(invasive), uterine corpus, ovary, and other uterine adnexa.
Decreased incidence of cancer in lip, oral cavity and pharynx,
stomach, colorectum, liver, pancreas, lung, thyroid, other skin,
and prostate. female patients with schizophrenia had a higher
incidence of cancer overall, compared to the general population,
whereas male patients with schizophrenia had a lower incidence
of cancer overall. When female-specific cancers were excluded,
female patients with schizophrenia had similar incidence to the
general population. relative risk of cancer in patients with
schizophrenia is highest among patients aged 20-29. Effect is
seen across all cancer types. higher cancer risk for those with
earlier age of onset.
Females with schizophrenia and females with bipolar both had a
higher incidence of cancers overall, compared to the female
general population. Overall cancer SIR for people with
schizophrenia reduced gradually as age of onset increased, and
SIR became protective from age 50. Same decrease with females
but no protective effect after a certain age. Females with
schizophrenia had an increased risk of breast and body of uterus
cancers.

elevated incidence of cancer observed in people with
schizophrenia and bipolar disorder, compared to the SEER
population. Observed in all subgroups with the exception of men
with bipolar disorder. Elevated incidence of colorectal and breast
cancer. Men with schizophrenia had an increased risk of prostate
cancer--not observed in men with bipolar
male patients with schizophrenia had significantly reduced
incidence of cancer, especially for cancers of the respiratory,
genital, and urinary systems. Overall, cancer incidence in female
patients with schizophrenia was not different from the general
population. Male and female patients with schizophrenia
together, had a lower incidence of cancer. Elevated risk of
developing breast cancer in patients with schizophrenia. In
female patients, increased incidence of non-Hodgkin lymphoma.
lower incidence of lung cancer.
Male patients with schizophrenia had a significantly reduced
incidence of cancer. Reduction for females but not statistically
significant. Reduced incidence of skin and testicular cancer in
male patients with schizophrenia.
no difference in overall cancer incidence in people with SMI,
compared to those without SMI. No difference in specific cancers
either
no significant difference in the overall incidence of cancer. No
differences found by age group or period. Slightly decreased
incidence of overall cancer in males with schizophrenia and a
slightly increased incidence of overall cancer in females with
schizophrenia. People with schizophrenia had a significantly
higher incidence of cancers of the lung, esophagus, pancreas,
and breast. Males with schizophrenia had a lower incidence of
prostate cancer.
significantly reduced incidence of cancer among people with
schizophrenia, compared to the general population.
no difference in cancer incidence between people with psychotic
disorders and people without

IRR

124

0.89

0.85

0.94

age, calendar period,
somatic comorbidity,
substance abuse

Slightly lower cancer incidence in males with SMI. Females with
SMI had similar incidence of cancer overall to females without
SMI.

Exposed
Citation

Psychotic Disorder

subsample

Cancers

females
Truers et al.,
2011

schizophrenia and
other psychoses

all cancer

Unexposed

Crude

Total

Person
Time
(P-Y)
(IR)

Outcome

No
Outcome

Total

Person
Time (IR)

NR

NR

NR

NR

NR

NR

NR

NR

894

NR

NR

NR

4010

NR

Outcome

No
Outcome

NR
NR

Crude
incidence
measure

HR

Point
Estimate

0.85

125

Adjusted
lower
(95%)

0.51

upper
(95%)

1.42

Adjusted
Measure

Point
Estimate

lower
(95%)

upper
(95%)

Covariates

IRR

1.03

0.99

1.07

age, calendar period,
somatic comorbidity,
substance abuse

HR

0.94

0.56

1.58

age, gender

Other Findings

no significantly higher risk for cancer

Appendix 2I: Summary of findings table for studies which reported on cancer stage at diagnosis
Citation

Psychotic
Disorder

AhlgrénRimpiläinen
et al., 2020

non-affective
psychotic
disorders

Arffman et
al., 2019

non-affective
psychotic
disorders

Notes

Male

Cancers

Staging

stage I
(local)

breast

localmetastasized

lung

Female

stage
II

stage III
(regional)

stage IV
(metastasized)

missing

Total

stage I
(local)

1774

269

202

2245

localmetastasized

125

592

238

localmetastasized

45

259

stage II

stage
III

stage IV
(metastasized)

missing

Total

65218

5308

5308

75834

955

3589

15314

5025

23928

101

405

1393

5849

2042

9284

Crude
Measure

Point
Estimate

lower
(95%)

upper
(95%)

Adjusted
Measure

Point
Estimate

lower
(95%)

upper
(95%)

Covariates

age, time of
diagnosis

Baillargeon
et al., 2011

psychotic
disorders

colon

I-IV

662

933

586

576

819

3576

13133

18831

13853

10495

3718

60030

Bergamo et
al., 2014

schizophrenia

all cancer

I-IV

398

57

423

413

12

1303

24899

4292

29501

35596

1111

95399

Chang et al.,
2013

schizophrenia

all cancer

localmetastasized

57

36

93

18205

10143

28348

OR

1.13

0.75

1.72

logistic
(OR)

1.23

0.81

1.88

age, gender

bipolar disorder

localmetastasized

24

7

31

18205

10143

28348

OR

0.52

0.22

1.22

logistic
(OR)

0.55

0.24

1.3

age, gender

schizoaffective

localmetastasized

4

1

5

18205

10143

28348

OR

0.45

0.05

4.02

logistic
(OR)

0.47

0.05

4.38

age, gender

all cancer

local,
regional,
meta

53

gastric,
colorectal

I-IV

595

ordinal
logistic
regression
(RR)

1.86

1.72

2

age, gender,
comorbidity,
income,
smoking,
type of
cancer

all cancer

localmetastasized

3088

localmetastasized

4873

local,
regional,
meta

528

301

355

local,
regional,
meta

974

753

445

Cunningham
et al., 2015

Ishikawa et
al., 2016

Manderbacka
et al., 2017

schizophrenia,
bipolar
disorder,
schizoaffective
disorder
schizophrenia

psychotic
disorders

Male
Female

Toender et
al., 2018

schizophrenia,
bipolar
disorder,
schizoaffective
disorder

Male

Female

all cancer

402

38

11

10

112

4467

3021

483

845

170

2495

4347

1476

2237

5325

183311

90288

273599

3115

7988

212935

100205

313140

449

1633

97435

50908

58186

69511

276040

502

2674

123050

82125

46709

46808

298692

1622

126

277

557

8322

1805

730

9980

Other Findings

Elderly patients with
schizophrenia were less
likely to receive stageappropriate NSCLC
treatment compared to
those without
schizophrenia. When
analyzed according to
stage, patients with
schizophrenia were less
likely to undergo surgery
for stages I-IIIA, receive
combined RT and
chemotherapy for stage
IIIB or chemotherapy for
stage IV NSCLC.
No association between
diagnosis with any SMI
and advanced stage at
diagnosis, adjusting for
age, gender, type of
cancer, year of cancer
diagnosis, primary care
trust, ethnicity and
deprivation score for
income.

People with schizophrenia
had a higher proportion of
stage IV cancer (33.9%)
compared to those
without schizophrenia
(18.1%)

Appendix 3A: The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in
observational studies using routinely collected health data.

Item No.
Title and abstract
1

Introduction
Background
rationale
Objectives

2
3

Methods
Study Design
Setting

4
5

Participants

6

STROBE items

(a) Indicate the study’s design with a commonly used term
in the title or the abstract (b) Provide in the abstract an
informative and balanced summary of what was done and
what was found

Location in manuscript
where items are
reported
Pages 48 – 49

Explain the scientific background and rationale for the
investigation being reported
State specific objectives, including any prespecified
hypotheses

Pages 49 – 51

Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow-up, and data
collection
(a) Cohort study - Give the eligibility criteria, and the
sources and methods of selection of participants. Describe
methods of follow-up
Case-control study - Give the eligibility criteria, and the
sources and methods of case ascertainment and control
selection. Give the rationale for the choice of cases and
controls

Pages 52 – 55
Pages 52 – 56

RECORD items

Location in
manuscript
where items
are reported

RECORD 1.1: The type of data used should be specified in the title
or abstract. When possible, the name of the databases used should be
included.

Page 48

RECORD 1.2: If applicable, the geographic region and timeframe
within which the study took place should be reported in the title or
abstract.

Page 48

RECORD 1.3: If linkage between databases was conducted for the
study, this should be clearly stated in the title or abstract.

Page 48

RECORD 6.1: The methods of study population selection (such as
codes or algorithms used to identify subjects) should be listed in
detail. If this is not possible, an explanation should be provided.

Pages 53 – 54

Page 51

Pages 53 – 54

RECORD 6.2: Any validation studies of the codes or algorithms used
to select the population should be referenced. If validation was
conducted for this study and not published elsewhere, detailed
methods and results should be provided.
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Pages 53 – 54

Item No.

STROBE items

Location in manuscript
where items are
reported

Cross-sectional study - Give the eligibility criteria, and the
sources and methods of selection of participants

Variables

7

Data sources/
measurement

8

Bias
Study size
Quantitative
variables

9
10
11

Statistical
methods

12

(b) Cohort study - For matched studies, give matching
criteria and number of exposed and unexposed
Case-control study - For matched studies, give matching
criteria and the number of controls per case
Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria,
if applicable.

Page 54

For each variable of interest, give sources of data and details
of methods of assessment (measurement).
Describe comparability of assessment methods if there is
more than one group
Describe any efforts to address potential sources of bias
Explain how the study size was arrived at
Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen, and why
(a) Describe all statistical methods, including those used to
control for confounding
(b) Describe any methods used to examine subgroups and
interactions
(c) Explain how missing data were addressed
(d) Cohort study - If applicable, explain how loss to followup was addressed
Case-control study - If applicable, explain how matching of
cases and controls was addressed
Cross-sectional study - If applicable, describe analytical
methods taking account of sampling strategy
(e) Describe any sensitivity analyses

Appendix 3B

Pages 55 - 56

RECORD items

Location in
manuscript
where items
are reported

RECORD 6.3: If the study involved linkage of databases, consider
use of a flow diagram or other graphical display to demonstrate the
data linkage process, including the number of individuals with linked
data at each stage.

Appendices 3C,
3D

RECORD 7.1: A complete list of codes and algorithms used to
classify exposures, outcomes, confounders, and effect modifiers
should be provided. If these cannot be reported, an explanation
should be provided.

Appendix 3B

RECORD 12.1: Authors should describe the extent to which the
investigators had access to the database population used to create the
study population.

Pages 53 – 54

Appendix 3B
Pages 53 - 58
Appendices 3C, 3D
Pages 56 – 57
Pages 56 – 57
Pages 56 – 57
Pages 56 – 57
Pages 56 – 57

Pages 56 – 57
Data access
and cleaning
methods

..
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Item No.

Linkage

Results
Participants

Descriptive
data

STROBE items

Location in manuscript
where items are
reported

RECORD 12.2: Authors should provide information on the data
cleaning methods used in the study.
RECORD 12.3: State whether the study included person-level,
institutional-level, or other data linkage across two or more
databases. The methods of linkage and methods of linkage quality
evaluation should be provided.

..

13

14

Outcome data

15

Main results

16

(a) Report the numbers of individuals at each stage of the
study (e.g., numbers potentially eligible, examined for
eligibility, confirmed eligible, included in the study,
completing follow-up, and analysed)
(b) Give reasons for non-participation at each stage.
(c) Consider use of a flow diagram
(a) Give characteristics of study participants (e.g.,
demographic, clinical, social) and information on exposures
and potential confounders
(b) Indicate the number of participants with missing data for
each variable of interest
(c) Cohort study - summarise follow-up time (e.g., average
and total amount)
Cohort study - Report numbers of outcome events or
summary measures over time
Case-control study - Report numbers in each exposure
category, or summary measures of exposure
Cross-sectional study - Report numbers of outcome events
or summary measures
(a) Give unadjusted estimates and, if applicable, confounderadjusted estimates and their precision (e.g., 95% confidence
interval). Make clear which confounders were adjusted for
and why they were included
(b) Report category boundaries when continuous variables
were categorized
(c) If relevant, consider translating estimates of relative risk
into absolute risk for a meaningful time period

RECORD items

Appendices 3C, 3D

Appendices 3C, 3D

Page 58 and table 3.1

Appendices 3C, 3D
Page 59
Pages 59 – 60

Pages 59 – 60
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RECORD 13.1: Describe in detail the selection of the persons
included in the study (i.e., study population selection) including
filtering based on data quality, data availability and linkage. The
selection of included persons can be described in the text and/or by
means of the study flow diagram.

Location in
manuscript
where items
are reported

Pages 53 – 54

Appendices 3C,
3D

Item No.

STROBE items

Location in manuscript
where items are
reported

Other analyses

17

Report other analyses done—e.g., analyses of subgroups and
interactions, and sensitivity analyses

Pages 59 – 60

Discussion
Key results

18

Summarise key results with reference to study objectives

Pages 60 – 65

Limitations

19

Discuss limitations of the study, taking into account sources
of potential bias or imprecision. Discuss both direction and
magnitude of any potential bias

Pages 66 – 67

Interpretation

20

Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
Discuss the generalisability (external validity) of the study
results

Pages 60 – 65

Give the source of funding and the role of the funders for the
present study and, if applicable, for the original study on
which the present article is based
..

Pages 67 – 68

Generalisabilit 21
y
Other Information
Funding
22

Accessibility
of protocol,
raw data, and
programming
code

RECORD items

Location in
manuscript
where items
are reported

RECORD 19.1: Discuss the implications of using data that were not
created or collected to answer the specific research question(s).
Include discussion of misclassification bias, unmeasured
confounding, missing data, and changing eligibility over time, as
they pertain to the study being reported.

Pages 66 – 67

RECORD 22.1: Authors should provide information on how to
access any supplemental information such as the study protocol, raw
data, or programming code.

Appendix 3

Pages 66 – 67
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Appendix 3B: Derivation of exposure, outcome, and confounding variables
Variable Name

Source of
Data

Description

Variable Name in
Database

Values and Database Codes

Binary group membership - To be classified in the exposed group as a case of psychotic disorder, people
must meet at least one of the following criteria:
(1) at least one primary discharge diagnosis (dxtype=M, dx10code) of schizophrenia, schizoaffective
disorder, schizophreniform, or psychosis NOS in the DAD database (see appendix B1 for
diagnostic codes)
OR
(2) at least two OHIP billings within 24 months with a diagnostic code (DXCODE) for
schizophrenia, schizoaffective disorder, schizophreniform, or psychosis NOS in the OHIP claims
database (see appendix B1 for diagnostic codes)
Date of first diagnosis of non-affective psychotic disorder

N/A

Exposed (1) vs unexposed (0)

N/A

Date (DDMMYYYY)

Main Comparison Groups
Exposed

DAD, OHIP

Index Date

DAD, OHIP

Baseline Socio-Demographic Characteristics
Age at Index Date

RPDB

Age at index date

BDATE

Gender

RPDB

Recorded sex

Rural Residence

RPDB

Rural place of residence, defined using the Rurality Index of Ontario. Areas with score of 40 or above are
considered rural.

Income Quintile

RPDB

Neighbourhood-level income quintile

Access to a family
physician

PCPOP

Person is assigned to a FP in PCPOP database closest to the index date

SEX
RIO2008
INCQUINT

Censoring events
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R_TYPE

Continuous variable calculated based
on index date and birth date

1 = Male
2 = Female
1 = Rural
0 = Non-Rural
1 = Lowest Income Quintile
5 = Highest Income Quintile
0 = no regular FP
1 = regular FP

Variable Name

Source of
Data

Description

Variable Name in
Database

Values and Database Codes

Censored

N/A

Censored at end observation time

N/A

1 = censored
0 = not censored

Censored date

N/A

Date of first censoring event

N/A

Date (DDMMYYYY)

Reason for Censoring

RPDB,
OHIP, DAD

Reason for censoring at the end of the observation time

N/A

Observation Time

N/A

Time (in days) between index and end of observation (first of cancer_dxdate or censored_date).

N/A

0 = not censored developed cancer at
the end of the observation time
1 = death as recorded in RPDB
2 = Maximum follow-up date
(December 31, 2019)
3 = New onset of non-affective
psychotic disorder (unexposed group
only)
Time in days

Cancer

OCR

Person identified in the OCR during the follow-up

N/A

Cancer diagnosis date

OCR

First date of incident cancer diagnosis

Cancer site

OCR

Site of primary tumour

CURR_TOPOG_CD

OCR ICD-O-3 Topography Code
(see appendix B2)

Cancer stage

OCR

Stage of cancer at diagnosis

BEST_STAGE_GRP

Roman numeral staging (I, II, III, IV)
derived from TNM staging

Outcomes

DXDATE
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1 = incident cancer case identified in
OCR during follow-up
0 = No incident cancer case identified
in OCR during follow-up
Date (DDMMYYYY)

Appendix 3C: Cohort Build for exposed group
Cohort build:
Exposed group

DAD

Ambulatory
# Patients

Step

Description

# Patients

#Excluded

remaining

#Excluded

remaining

Diagnosis of non-affective psychosis
identified using case definition
1

between 1995 and 2005

-

116,982

-

15,392

2

Total BEFORE exclusions

-

116,982

-

15,392

3

Age <18 or >=60 at index

31,620

85,362

7,149

8,243

0

85,362

0

8,243

1,241

84,121

34

8,209

Invalid/missing data in age and sex
4

variables

5

Non-Ontario resident

6

Not eligible for OHIP in past year

572

83,549

114

8,095

7

Death date < index date

<=5

NR

0

8,095

1,223

82,323

202

7,893

23,803

58,520

1,239

6,654

0

58,520

0

6,654

58,459

58,520

8,738

6,654

Presence of IKN in OCR from 1964
8

to index date
evidence of non-affective psychosis
(diagnostic codes listed in appendix
A) within 5 years prior to beginning

9

of accrual period

10

After frequency match

11

Total AFTER cohort build exclusions
Remaining patients from BOTH

12

databases

65,174

Excluded for cancer diagnosis on
index date, diagnosis with stage 0
cancer, or invalid/missing data in
income, rurality, and access to family
physician variables

63,410

Total AFTER exclusions

63,410
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1,764

Appendix 3D: Cohort build for unexposed group
Cohort build:
Unexposed group
Step
1
2
3
4
5
6
7
8
9
10
11

RPDB
Description

#Excluded

# Patients
remaining

7,709,580
0
607,467
2,249,342
1,389

18,218,136
18,218,136
10,508,556
10,508,556
9,901,089
7,651,747
7,650,358

Individuals in RPDB who are alive, in Ontario and
born after 1935 as of Jan 1, 1995
Total BEFORE exclusions
Age <18 or >=60 at index
Invalid/missing data in age and sex variables
Non-Ontario resident
Not eligible for OHIP in past year
Death date < index date
Presence of IKN in OCR from 1964 to December
2004
In the exposed cohort
Evidence of schizophrenia, schizoaffective disorder,
or psychosis NOS within 5 years of index date
After frequency match
Total AFTER cohort build exclusions

93,225
57,281

7,557,133
7,499,852

24,425
7,214,731
17,957,440

7,475,427
260,696
260,696

Excluded for cancer diagnosis on index date,
diagnosis with stage 0 cancer, or invalid/missing data
in income, rurality, and access to family physician
variables

10,157

250,539

134

Appendix 3E: Results of age- and sex-stratified Poisson models of cancer incidence in people
with NAPD, relative those without NAPD
Category
Ages 15 —19
Ages 20 – 29
Ages 30 –39
Ages 40 –49
Ages 50 – 59
Remove all gender specific
Male
All ages male
15 – 19
20 – 29
30 – 39
40 – 49
50 – 59
Males with all male-specific cancers removed:
testes, prostate
Males, excluding prostate cancer
Males, excluding testicular cancer
Female
All ages female
15 – 19
20 – 29
30 – 39
40 – 49
50 – 59
Females, excluding breast
Females, excluding cervical
Females, excluding ovarian
Females, excluding uterine
All ages female (female-specific cancers
removed: breast, cervix, ovary, uterus)

IRR
0.92
1.00
1.10
1.08
1.10
1.17

95% CI lower limit
0.71
0.89
1.03
1.03
1.04
1.13

95% CI upper limit
1.21
1.14
1.19
1.14
1.15
1.22

1.01
1.08
1.05
1.05
1.00
0.99
1.15

0.97
0.77
0.88
0.94
0.93
0.92
1.09

1.06
1.51
1.26
1.17
1.09
1.06
1.21

1.15
1.01

1.10
0.96

1.21
1.05

1.15
0.73
0.96
1.14
1.15
1.19
1.19
1.15
1.16
1.15
1.20

1.11
0.47
0.80
1.04
1.07
1.12
1.13
1.10
1.12
1.10
1.13

1.20
1.14
1.15
1.26
1.23
1.28
1.25
1.20
1.21
1.20
1.27
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